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ABSTRACT 
 
Complement activation-related pseudoallergy (CARPA) is a term refers to those 
hypersensitivity reactions where the allergen can activate complement. This study 
examined the effect of nanomedicines and polyethylene glycol on complement activation. 
Single-walled carbon nanotubes, which have many medical applications as drug delivery 
systems, activated human complement independently of the C1q-dependent classical and 
the alternative pathways, as reflected by a significant rise in serum levels of S-protein 
bound form of terminal complex (SC5b-9) and C4d. This study also shows that 
polyethylene glycol (PEG) with different molecular weights was capable of activating 
complement. It was found that molecular weight of PEG plays an important role in 
activating both calcium sensitive and alternative pathways of the human complement 
system, with relatively higher molecular weight polymer resulting in more activation to a 
certain extent. 
Methoxypoly(ethylene glycol), (mPEG),-grafted liposomes are known to exhibit 
prolonged circulation time in the blood, but these liposomes are believed to cause 
anaphylatoxin production through complement activation. Despite the general view that 
vesicle surface grafted with mPEG should suppress complement activation, this study 
shows that bilayer enrichment of non-complement activating liposomes (DPPC) vesicles 
with phospholipids-mPEG conjugate induce complement activation resulting in vesicle 
recognition by macrophage complement receptors. This work has successfully delineated 
the likely structural features of phospholipids-mPEG conjugate responsible for 
PEGylated liposome-induced complement activation in normal as well as C1q-deficient 
human sera, using DPPC vesicles bearing the classical as well as newly synthesized lipid-
mPEG conjugates. With PEGylated DPPC vesicles, the net anionic charge on the 
phosphate moiety of phospholipids-mPEG conjugate played a key role in activation of 
both classical and alternative pathways of complement and anaphylatoxin production. 
Since methylation of the phosphate oxygen of phospholipids-mPEG conjugate, and hence 
the removal of the negative charge, totally prevented complement activation. 
These findings provide a rational conceptual basis for development of safer vesicles for 
site-specific drug delivery and controlled release at pathological sites. This study has also 
examined liposome-mediated complement activation in human sera with elevated 
lipoprotein (LDL and HDL) levels, since abnormal or racial differences in serum lipid 
profiles seem to modulate the extent of complement activation and associated adverse 
responses. Cholestrol-rich (45 mol% cholesterol) liposomes activated human 
complement. However, liposome-induced rise of SC5b-9 was significantly suppressed 
when serum HDL cholesterol levels increased by 30%. Increase of serum LDL to levels 
similar to that observed in heterozygous familial hypercholesterolemia also suppressed 
liposome-mediated SC5b-9 generation considerably. While intravenous injection of 
cholesterol-rich liposomes into pigs was associated with an immediate circulatory 
collapse, the drop in systemic arterial pressure following injection of liposome 
preincubated with human lipoproteins was slow and extended. Therefore, surface-
associated lipoprotein particles (or apolipoproteins) seem to lessen liposome-induced 
adverse haemodynamic changes, possibly as a consequence of suppressed complement 
activation in vivo. The presence of projected methoxypoly(ethylene glycol) chains did not 
interfere with generation of C3 opsonic fragments. Moreover, this study shows that PEG 
is not responsible for PEGylated liposome-mediated complement activation.  
 
  
TABLE OF CONTENTS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter one 
 
1.1 
 
 
1.2 
 
 
1.2.1 
 
1.2.2 
 
1.2.3 
 
1.2.4 
 
1.3 
 
1.4 
 
 
1.5 
 
1.6 
 
1.6.1 
Abstract 
 
Table of contents 
 
List of figures 
 
List of tables 
 
List of abbreviations 
 
Acknowledgments 
 
Dedications 
 
Declaration 
 
Publications 
 
Introduction 
 
Nanomedicines: hypersensitivity reactions, causative 
factors and optimization of design parameters 
 
Nanomedicine as drug delivery: applications and 
possible complement-mediated hypersensitivity 
 
Non-ionic polymers 
 
Polyethylene glycol 
 
Stealth liposomes 
 
Carbon nanotubes 
 
Fate of intravenously injected nanoparticles 
 
The influence of surface PEGylation on complement 
activation 
 
Opsonization and phagocytosis 
Over view of the complement system 
I 
 
II 
 
VII 
 
IX 
 
X 
 
XI 
 
XII 
 
XIII 
 
XIV 
 
1 
 
2 
 
 
5 
 
 
10 
 
12 
 
13 
 
15 
 
17 
 
18 
 
 
20 
 
21 
 
22 
  
 
1.6.2 
 
1.6.3 
 
1.7 
 
Chapter two 
 
 
 
 
2.1 
 
2.2 
 
2.2.1 
 
2.2.2 
 
2.2.2.1 
 
2.2.2.2 
 
 
2.2.2.3 
 
2.2.2.4 
 
2.2.2.5 
 
 
2.3 
 
2.3.1 
 
2.3.2 
 
2.3.3 
 
2.3.4 
 
2.3.5 
 
 
2.3.6 
 
The classical pathway 
The alternative pathway 
 
The lectin pathway 
 
Aims of the project 
 
Methylation of the phosphate oxygen moiety of 
phospholipid-methoxy(polyethylene glycol) conjugate 
prevents PEGylated liposome-mediated complement 
activation and anaphylatoxin production 
 
Introduction 
 
Materials and methods 
 
Materials 
 
Methods 
 
Synthesis of phospholipid-mPEG conjugates 
 
Preparation and characterization of liposomes and 
phospholipids-mPEG micelles 
 
Collection and treatment of serum specimens 
 
Assay of in vitro complement activation 
 
Determination of complement hemolytic activity and 
TXB2 level in rat blood                             
 
Results and discussion 
 
Conjugate synthesis and rationale for liposome design 
 
Liposome-mediated complement activation in vitro 
 
The effect of surface mPEG-density and vesicle size 
 
Liposome-mediated complement activation in rats 
 
The involvement of both classical and alternative 
pathways 
 
The role of phospholipid head-group—A hypothesis 
 
22 
 
23 
 
25 
 
26 
 
 
 
 
27 
 
29 
 
29 
 
30 
 
30 
 
32 
 
 
32 
 
33 
 
34 
 
 
34 
 
34 
 
36 
 
41 
 
45 
 
45 
 
 
50 
 
  
2.4 
 
Chapter three 
 
 
 
3.1 
 
3.2 
 
3.2.1 
 
3.2.2 
3.2.2.1 
3.2.2.2 
3.2.2.3 
3.2.2.4 
3.2.2.5 
 
3.3 
3.4 
 
Chapter four 
 
4.1 
4.2 
4.2.1 
4.2.2 
4.2.2.1 
 
Conclusion  
 
Complement Activation by PEGylated Single-Walled 
Carbon Nanotubes is Independent of the C1q-
Dependent Classical and the Alternative Pathways 
 
Introduction 
 
Materials and methods 
 
Materials 
 
Methods 
 
Preparation of PEGylated SWNTs 
 
PEGylate liposomes 
 
Preparation of human serum 
 
Assays of in vitro complement activation 
 
Determination of thromboxane B2 (TXB2) level in rat 
blood 
 
 
Results and Discussion 
Conclusion 
 
 
Poly(ethylene glycol)s trigger complement activation in 
human serum through alternative and lectin pathways: 
a plausible cause for anaphylaxis 
 
Introduction 
 
Materials and methods 
 
Materials 
 
Methods 
 
PEG diacetylation 
 
52 
 
55 
 
 
 
56 
 
58 
 
58 
 
59 
 
59 
 
59 
 
59 
 
60 
 
62 
 
 
 
62 
 
75 
 
 
 
77 
 
 
78 
 
 
80 
 
80 
 
81 
 
81 
 
81 
  
4.2.2.2 
4.2.2.3 
Liposome preparation 
 
Preparation of human serum 
 
 
 
 
 
82 
 
   
 
4.2.2.4 Assays of in vitro complement activation 
 
 
84 
4.2.2.5 SDS-PAGE and Western blot analyses 
 
 
85 
4.3 Results and discussion 86 
4.3.1 Activation of the whole complement pathway 
 
 
86 
4.3.2 Alternative pathway mode of activation 
 
 
92 
4.3.3 C4-Dependent complement activation 
 
 
94 
4.3.4 Kinetics of PEG-mediated complement activation 
 
 
105 
4.4 Conclusion 
 
108 
Chapter five Activation of the Human Complement System by 
Cholesterol-Rich and PEGylated Liposomes—
Modulation of Cholesterol-Rich Liposome-Mediated 
Complement Activation by Elevated Serum LDL and 
HDL Levels 
 
110 
5.1 Introduction  
 
 
111 
5.2 Materials and Methods 112 
  
 
 
5.2.1 Materials 
 
 
112 
5.2.2 Methods 
 
 
113 
5.2.2.1 Preparation of liposomes 
 
 
113 
5.2.2.2 Subject and collection of serum specimen 
 
 
113 
5.2.2.3 
 
5.2.2.4 
Assay of in vitro complement activation 
 
In vivo Closed-Chest Instrumented Pig 
 
 
113 
 
114 
5.3 Results and Discussion 
 
115 
5.4 Conclusion 
 
 
120 
Chapter six General conclusions and suggestions for future work 
 
 
122 
Chapter seven References 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LIST OF FIGURES 
 
Fig. 1.1 Complement activation pathways 
 
24 
Fig. 2.1 Synthetic pathway and chemical structures of pro-drug ether 
lipid-mPEG conjugates (Conj-A and Conj-B) 
 
31 
Fig. 2.2.a Effect of liposomes on complement activation: SC5b-9 levels 
 
38 
Fig. 2.2.b Effect of liposomes on complement activation: the effect of 1-
O-DPPC bearing liposomes (70–110 nm) on SC5b-9 
generation in serum 
 
39 
Fig. 2.2.c Effect of liposomes on complement activation: the influence 
of lipid-mPEG conjugates (5 mol%) on DPPC liposome-
mediated anaphylatoxin generation 
 
40 
Fig. 2.3 The effect of near monodisperse PEG1960 and PEG400 on 
complement activation. 
 
42 
Fig. 2.4 Plasma TXB2 levels in rats following bolus intravenous 
injection of liposomes 
 
46 
Fig. 2.5 SC5b-9 generation in C1q-depleted human serum 
 
49 
Fig. 3.1 An atomic force microscope image of amino-PEG5000-DSPE 
functionalized SWNTs over a SiO2 substrate 
 
64 
Fig. 3.2 PEGylated SWNT-mediated complement activation in 
human serum 
 
65 
Fig. 3.3 PEGylated SWNT-mediated rises of the fluid phase C4d in 
C1q-depleted human serum 
 
69 
Fig. 3.4 Plasma TXB2 levels in rats following bolus intravenous 
injection of PEGylated SWNTs, PEG-PL conjugates and 
PEGylated liposomes 
 
73 
Fig. 3.5 Proposed schematic representation of SWNT-mediated 
complement activation via the lectin pathway 
 
74 
Fig. 4.1a Complement activation as a function of PEG1960 
concentration: PEG1960-mediated rises of SC5b-9 over 
background 
 
87 
  
Fig. 4.1b Complement activation as a function of PEG4240 
concentration 
88 
Fig. 4.1c Complement activation as a function of PEG8350 
concentration: PEG8350-mediated rises of SC5b-9 over 
background 
 
89 
Fig. 4.1d Complement activation as a function of PEG11600 
concentration: PEG11600-mediated rises of SC5b-9 over 
background 
 
90 
Fig. 4.1e The influence of different molecular weights of PEG on 
anaphylatoxin C3a-desArg 
 
91 
Fig. 4.2a Elevation of complement split-product Bb as a function of 
PEG molar concentration and molecular mass 
 
95 
Fig. 4.2b Elevation of complement split-product C4d as a function of 
PEG molar concentration and molecular mass 
 
96 
Fig. 4.3a PEG-mediated elevation of complement activation products 
SC5b-9, Bb and C4d in C2-depleted human serum 
 
97 
Fig. 4.3b Western blot analysis of PEG-induced protein aggregates for 
factor H in normal serum 
 
98 
Fig. 4.4a Comparison of PEG- and cholesterol-rich liposome-mediated 
complement activation in EGTA/Mg
2+
-treated sera 
 
101 
Fig. 4.4b Comparison of PEG- and cholesterol-rich liposome-mediated 
complement activation in EGTA/Mg
2+
-treated sera 
 
102 
Fig. 4.5a The effect of native and acetylated PEG4240 on C4d 
generation in C1q-depleted human serum 
 
103 
Fig. 4.5b   The chemical structure of acetylated PEG 
 
104 
Fig. 4.6a PEG11600-mediated SC5b-9 generation in a normal serum 
over time 
 
106 
Fig. 4.6b PEG11600-mediated Bb generation in a normal serum over 
time 
 
107 
Fig. 5.1 The effect of human lipoproteins on liposome-mediated 
complement activation: Generation of SC5b-9 in human 
serum 
 
118 
  
Fig. 5.2 The effect of human lipoproteins on liposome-mediated 
complement activation: Mean systemic arterial blood 
pressure in  a pig following injection of liposomes  
 
119 
   
  
List of tables 
 
 
 
Table 2.1 The effect of liposome size and bilayer composition on SC5b-
9 generation in human serum 
 
43 
Table 4.1 PEG characteristics 
 
83 
   
   
   
   
   
   
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 List of abbreviations  
   
 Cardiac Output CO 
 Central Venous Pressure CVP 
 Complement Activation-Related Pseudoallergy CARPA 
 Dipalmitoylphosphatidylcholine DPPC 
 Dipalmitoylphosphatidylethanolamine DPPE 
 Dipalmitoylphosphatidylglycerol DPPG 
 Distearoylphosphatidylethanolamine DSPE 
 Enzyme-Linked Immunosorbent Assay ELISA 
 Ethylenebis (oxyethylene-trinitrilo)tetraacetic acid EGTA 
 Ethylenediaminetetraacetic Acid EDTA 
 High-Density Lipoprotein  HDL 
 Hypersensitivity Reactions HSR 
 Left Ventricular End-diastolic Pressure LVEDP 
 Low-Density Lipoprotein LDL 
 Mannan-associated Serine Protease-1 MASP-1 
 Mannan-associated Serine Protease-2 MASP-2 
 Mannan-associated Serine Protease-3 MASP-3 
 Mannan-Binding Lectin MBL 
 Membrane Attack Complex MAC 
 Methoxy(Polyethylene Glycol) mPEG 
 Multilamelar vesicles MLV 
 Nuclear Magnetic Resonance NMR 
 Phosphate-buffered Saline PBS 
 Polyethylene-Glycol PEG 
 Pulmonary Artery Pressure PAP 
 Pulmonary Vascular Resistance  PVR 
 Radiocontrast Media RCM 
 Reticuloendothelial System RES 
 Secretary Phospholipase A2  sPLA2 
 Single-walled Nanotubes SWNT 
 Systemic Arterial Pressure SAP 
 Systemic Vascular Resistance SVR 
 Thromboxane-A2 TXA2 
 Thromboxane-B2 TXB2 
   
   
   
   
   
   
   
   
   
   
 
  
 
 
Acknowledgments 
All thanks to Allah. From the formative stages of this thesis, to the final draft, I owe an 
immense debt of gratitude to my supervisor, Dr. Seyed Moghimi. His sound advice and 
careful guidance were invaluable providing brilliant guidance and extraordinary advice 
throughout my research. I also owe a lot for my co-supervisor, Dr. Christy Hunter who 
was always there for me giving priceless help and guidance and contributing significantly 
to this work.  
My sincere thanks to Professor Szebeni from Hungary for his considerable help and 
collaboration especially with the in-vivo work. 
I am thankful to the research group in the Technical University of Denmark for their help, 
mainly in the development of the new conjugate.   
Also, I would be remiss without mentioning all technicians and other members of PABS 
department for their support especially Christine Smith, whose extreme generosity will be 
remembered always. 
A big thank you to all staff in the school office for their continuous help. Mentioning here 
Mrs. Sara Flux and Mrs. Mairead Sticking. 
Last but not least, I give all my love and regards to my sisters and brothers back home for 
the support and patience they showed during my research.   
To each of the above, I extend my deepest appreciation. 
  
 
 
 
 
 
Dedication 
 
For my beloved parents, who offered me unconditional love and support 
throughout the course of this thesis. I am infinitely in debt to you.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Declaration 
 
This work has not previously been accepted in substance for any degree  
 
and is not being currently submitted in candidature for any degree 
 
 
Date:……………….. 
 
 
Signature:………………………. 
 
Statement one:  
 
This thesis is the result of my own work and investigations, except where  
 
otherwise stated. Other sources are acknowledged by footnotes giving 
 
explicit references 
 
Statement two 
 
I here give consent for my thesis, if accepted to be available for  
 
photocopying and for interlibrary loan and for the title and summary to be  
 
made available to outside organization  
 
 
Date:……………….. 
 
 
Signature:………………………. 
 
 
 
 
 
  
 
 
 
 
 
Publications, conference contributions and published book chapters 
 
* Hamad I and Moghimi SM (2008). Critical issues in site-specific targeting of solid 
 tumours; the carrier, the tumour and the bioavailable drug. Expert Opinion on Drug 
Delivery.  5: 205–219. 
 
* Moghimi SM, Hamad I, Andresen T, Jørgensen K, Szebeni J (2006). Methylation of 
the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate 
prevents PEGylated liposome-mediated complement activation and anaphylatoxin 
production. FASEB J. 20:E2057–E2067. 
* Moghimi SM, Hamad I, Bunger R, Anderson TL, Jørgensen K Hunter AC, Baranji L, 
Rosivall L, Szebeni J (2006). Activation of the human complement system by 
cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-
mediated complement activation by elevated serum LDL and HDL levels. Journal of 
Liposome Research. 16(3):167-74. 
* S Moein Moghimi, Islam Hamad & A Christy Hunter (2007). Particulate 
nanomedicine in the footsteps of platelet homing: Evaluation of: Simberg D, Duza T, 
Park JH et al.: Biomimetic amplification of nanoparticle homing to tumors. 
Nanomedicine. 2, (3): 381-384. 
  
* Moghimi, S. M. and Hamad, I. (2008)    Hypersensitivity reactions to nanomedicines: 
Causative factors and optimization of design parameters.  In: Allergy Frontiers: from 
Epigenetics to Future Prespectives (R. Pawankar, S. Holdgate, L. J. Rosenwaser, eds.). 
Springer Japan KK, Tokyo (in press). 
 
* Moghimi, S. M. and Hamad, I. (2008) Factors controlling pharmacokinetics of 
intravenously injected nanoparticles. In: Biotechnology: Pharmaceutical Aspects, 
Nanotechnology in Drug Delivery (M. M. de Villiers, G. S. Kwon, eds.). Springer 
Science (in press). 
* I Hamad, AC Hunter, J Szebeni, SM Moghimi (2008). Poly(ethylene glycol)s trigger 
complement activation in human serum through alternative and lectin pathways: a 
plausible cause for anaphylaxis. Paper submitted. 
* Islam Hamad, A. Christy Hunter, Kenneth J. Rutt,  Zhuang Liu, Hongjie Dai, and S. 
Moein Moghimi. (2008). Complement Activation by PEGylated Single-Walled Carbon 
Nanotubes is Independent of C1q-Dependent Classical and Alternative Pathways. 
Molecular immunology, in press.  
* Moghimi SM and Hamad I. Complement activation by polymers and polymeric 
constructs. New frontiers in nanomedicine Conference. London UK. Oct 15-15
th
 2007. 
  
* Moghimi SM and Hamad I. Liposome advances, progress in drug and vaccine 
delivery. 3
rd
 International Liposomes society meeting. School of Pharmacy, London 
University. UK. 8 -11th Dec 2007. 
* Hamad I, Hunter AC, Moghimi SM. Complement activation by the thermosensitive 
block co-polymer poloxamer 407: Implications in vascular medicines. Lipid disorders. 
Gladstone institute of cardiovascular diseases. SF, California USA. Jan 31-feb 2 (2008). 
 
* Moghimi, S. M. and Hamad, I. (2009) Liposome-mediated triggering of complement 
cascade. In: Methods in Molecular Biology: Liposomes (V. Weissig, ed.). Humana Press 
Inc., Totowa, NJ. (in press). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter one: 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1.1 Nanomedicines: hypersensitivity reactions, causative factors and 
optimization of design parameters 
Advances in nanomedicine are beginning to transform the detection/diagnosis and 
treatment of disease, and are turning promising molecular discoveries into benefits for 
patients. Examples of nanomedicines (ranging in size from a few to hundreds of 
nanometers) that have been administered into the body include liposomes, 
polymericnanospheres, micelles, late-generation dendrimers, protein cages, vault 
nanocapsules, composite nanoshells, iron oxide nanocrystals and carbon nanotubes 
(Moghimi et al., 2005; Moghimi & Kissel, 2006). Some of these entities (e.g., liposomes 
and polymeric nanospheres) can efficiently encapsulate or incorporate drug molecules, 
thus following administration affording protection against drug degradation or 
inactivation en-route to the target site (Moghimi & Hamad, 2008). This may even result 
in a reduction of the amount of active agent needed to obtain a beneficial effect, and may 
effectively reduce drug-induced toxicity and other side effects (Moghimi et al., 2005).  
Encapsulation capacity, drug release profiles (over a period of days or even weeks), and 
biological performance of nanomedicines vary with parameters such as chemical make-
up, morphology and size (Moghimi et al., 2005). These parameters can be tailored in 
relation to the type, developmental stage and location of given disease. For instance, 
intravenously injected polymeric nanoparticles and liposomes are rapidly intercepted by 
the hepatic and splenic macrophages (Moghimi et al., 2005). This propensity of 
macrophages for the phagocytic/endocytic clearance of foreign entities provides a 
rational approach to macrophage-specific delivery of drugs, toxins, antigens and 
diagnostic agents (Moghimi et al., 2005). Indeed, liposome-mediated macrophage suicide 
(ie, delivery of macrophage toxins) has proved to be a powerful approach in removing 
  
unwanted macrophages during gene therapy, or in autoimmune blood disorders or spinal 
cord injury (Moghimi & Hamad, 2008). Furthermore, nanomedicines can be engineered 
to be pH-sensitive or fusion-competent; these properties aid the release of their entrapped 
cargo from endo-lysomal compartment into the cytosol within minutes of internalization 
(Drummond et al., 2000; Panyam et al., 2002). Alternatively, pharmacokinetic profiles of 
nanoparticels can be altered by tailoring their size, shape and surface properties (e.g., by 
polymer grafting), thus providing opportunities for targeting to non-macrophage sites 
(Moghimi et al., 2001). For example, “macrophage-evading” drug carriers of ≤ 150 nm in 
size exhibit prolonged circulation times in the blood and may escape from the vasculature 
at sites where capillaries have open fenestrations or when the integrity of the endothelial 
barrier is perturbed by inflammatory processes or tumour growth (Moghimi & Hamad, 
2008). Indeed, there are many reported cases for successful delivery of drugs and contrast 
agents with different long-circulating entities to the underlying parenchyma of solid 
tumours and injured arteries (Moghimi et al., and 2001).  
The biggest commercial opportunities in the nanomedicine sector are envisaged to arise 
from the development of multifunctional entities capable of simultaneously detecting and 
treating diseases, as well as for follow-up monitoring of particular pathology. Here, 
advances in development of composite metal nanoshells, iron oxide nanocrystals and 
carbon nanotubes have been of paramount importance (Moghimi & Kissel, 2006). As a 
result of their nanosize (and hence different atomic arrangements), these materials exhibit 
a wide spectrum of unique physical and chemical properties (Moghimi et al., 2005; 
Moghimi & Kissel, 2006). Composite metal nanoshells, for example, consist of a 
spherical dielectric core of 20-80 nm (e.g., made from silica) surrounded by a thin metal 
shell of 5-20 nm (e.g., made from gold). In such entities, incident light can couple to the 
  
Plasmon excitation of the metal; a process that involves the light-induced motion of all 
valence electrons. Consequently, the type of Plasmon that exists on the surface of a 
metallic nanoparticle is directly related to the shape and curvature of the nanoparticle. 
Hence, by controlling the relative thickness of the core and shell layers, the Plasmon 
resonance and resultant optical absorption properties can be adjusted near UV to mid-
infrared (Hirsch et al., 2006). Drugs can be incorporated within the nanoshell core, and 
the surface of nanoshell is further amenable for decoration with biological ligands and 
polymers for site-specific targeting. Such intravenous are more precise than 
chemotherapy (being targeted) and exert fewer side effects; they are also potentially less 
expensive and therefore more affordable to poorer countries (Moghimi & Hamad, 2008).  
However, as a consequence of their small size, composition and altered 
pharmacokinetics, nanomedicines may induce inflammatory reactions and adverse 
immune toxicity (Moghimi et al., 2005) for instance, acute allergic reactions with 
symptoms that fit in Coomb and Gell’s Type I category (but, which are initiated or 
mediated by pre-exsisting IgE antibodies) have been reported to occur following 
administration of clinically available nanomedicines (e.g., liposomes, micelles and 
polymeric nanospheres) (Sculier et al., 1986; Laing et al., 1994; Lavine et al., 1991; 
Richardson et al., 1997; Uziely et al., 1995; Kris et al., 1986; Grosen et al., 2000; Katten 
et al., 1992). An understanding of the causative and molecular basis of these reactions is 
of great importance, and could lead to better design and nanoengineering strategies for 
preventing hypersensitivity to future nanomedicines.   
 
 
  
1.2 Nanomedicine as drug delivery: applications and possible complement-mediated 
hypersensitivity 
Most of us are familiar with the best known of all immunological diseases, the allergies, 
usually called “hypersensitivities” by physicians. When a person has been 
immunologically prepared or sensitized to an antigen, either naturally or deliberately 
(vaccinated), immune response will not necessarily occur in later further exposure to the 
antigen. Tissue damage reactions can also occur in some cases. A simple definition of 
hypersensitivity reaction is an allergic disorder in which the body becomes hypersensitive 
to particular antigens, which provoke characteristic symptoms whenever they are 
subsequently encountered. Some hypersensitivity reactions are immediate and dramatic, 
such as sensitivity to insect stings or to drugs such as penicillin. Hypersensitivity 
reactions can be divided into four types: type I, type II, type III and type IV, based on the 
mechanisms involved and time taken for the reaction. Frequently, a particular clinical 
condition may involve more than one type of reaction. Types I III are antibody-mediated 
and are distinguished by the different types of antigens recognized and the different 
classes of antibody involved. Type I hypersensitivity is also known as immediate, atopic 
or anaphylactic hypersensitivity and the reaction may cause a range of symptoms from 
minor inconvenience to death (as in asthma). Immediate hypersensitivity is mediated by 
IgE and produced by the immediate release of histamine, tryptase, arachidonate and 
derivatives by basophils and mast cells. This causes an inflammatory response leading to 
an immediate (within seconds to minutes) reaction. This reaction could be local or 
systemic. Mild irritation to sudden death from anaphylactic shock could occur 
subsequently. Diagnostic tests for immediate hypersensitivity include skin (prick and 
intradermal) tests, measurement of total IgE and specific IgE antibodies against the 
  
suspected allergens. Treatment usually involves antihistamines and corticosteroids. Some 
examples of type I hypersensitivity reactions include: allergic asthma and rhinitis, 
anaphylaxis and urticaria.   
Type II hypersensitivity reactions (also known as cytotoxic hypersensitivity) involve 
immunoglobulin G or immunoglobulin M antibodies bound to cell surface antigens to 
form complexes that activate the classical pathway of complement activation for 
eliminating cells presenting foreign antigens (which are usually pathogens). These 
mediators of acute inflammation generated at the site and membrane attacking complex 
(MAC) cause cell lysis and death. The reaction time varies from minutes to hours up to a 
day. Diagnostic tests include detection of circulating antibody against the tissues involved 
and the presence of antibody and complement in the lesion (biopsy) by 
immunofluorescence. Treatment involves anti-inflammatory and immunosuppressive 
agents. Some examples of type II hypersensitivity reactions include: Autoimmune 
haemolytic anaemia, immune thrombocytopenia and tranfusion reactions.  
 Type III reactions (also known as immune-complex reactions) involve circulating 
antigen-antibody soluble immune complexes. They are mostly of the IgG class, although 
IgM may also be involved. In this case, the antigen is soluble and not attached to the cells 
involved. Primary components are soluble immune complexes and complement (C3a, 4a 
and 5a). These soluble immune complexes may trigger an immune response according to 
the classical pathway of complement activation. The reaction may take 3 - 10 hours after 
exposure to the antigen (as in Arthus reaction). Diagnosis involves examination of tissue 
biopsies for deposits of Ig and complement by immunofluorescence.  Treatment includes 
anti-inflammatory agents. Some examples of type III hypersensitivity reactions involve: 
rheumatoid arthritis, serum sickness, symptoms of malaria and Arthus reaction.  
  
The Forth and last type IV of reactions (usually called delayed hypersensitivity reactions 
as the reaction takes two to three days to develop, cell-mediated immunity) are unlike the 
other types mediated by antibodies but are type of T cells-mediated responses. Damages 
in delayed hypersensitivity include T lymphocytes and monocytes and/or macrophages. 
CD8 cytotoxic T cells and CD4 helper T cells recognize antigen in a complex with either 
type 1 or 2 major histocompatibility complex. Macrophages here play the role of antigen-
presenting cells which release a group of cytokines known as interleukin 1, which 
stimulates the proliferation of further CD4 cells. These cells release interleukin 2 and 
interferon gamma, further inducing the release of other Type 1 cytokines, thus mediating 
the immune response. Activated CD8 cells destroy target cells on contact while activated 
macrophages produce hydrolytic enzymes and, on presentation with certain intracellular 
pathogens, transform into multinucleated giant cells. In vitro tests for delayed 
hypersensitivity include mitogenic response, lympho-cytotoxicity and IL-2 production. 
While in vivo diagnosis includes delayed cutaneous reaction (e.g. Montoux test) and 
patch test (for contact dermatitis). Treatment in this type of hypersensitivity involves 
some immunosuppressive agents and corticosteroids. 
The agents released from mast cells include histamine, tryptase, proteoglycans, other 
chemotactic factors and leukotrienes. Mast cells may be triggered by other stimuli such as 
exercise, emotional stress, chemicals (e.g., photographic developing medium, calcium 
ionophores, codeine, etc.), anaphylotoxins (e.g., C4a, C3a, C5a, etc.). These reactions, 
mediated by agents without IgE-allergen interaction, are not hypersensitivity reactions 
although they produce the same symptoms. 
  
Some chemicals are known to cause an unusual hypersensitivity syndrome in certain 
population despite the intense premeditation and awareness being taken. These reactions 
are severe, life-threatening in up to 1-3% of patients with occasional deaths mostly due to 
cardiac arrest (Rowinsky et al., 1992; 1993b; 1995; Kris et al., 1986; Laher & karp, 1997; 
Tsavaris et al., 1998; Bookman et al., 1997; Hamad & Moghimi, 2008). Szebeni referred 
to these hypersensitivity reactions where the allergen can activate complement as 
complement activation-related pseudoallergy (CARPA) (Szebeni et al., 1999 and 2000). 
This phenomenon is increasingly recognized as an immune toxicity issue that has 
particular significance in the modern field of pharmaceutical nanotechnology (Hunter & 
Moghimi, 2002). Known examples of pseudoallergy include the reactions caused by 
radiocontrast media (RCM), nonsteroidal anti-inflammatory drugs, analgetics, morphine 
and insect venoms, liposomes and micellar solvents, such as Cremophor EL (CrEL) in 
Taxol. While there is no known common underlying cause for most of these reactions, 
there is substantial evidence suggesting that the reactions caused by RCM, liposomes and 
CrEL have a common trigger mechanism: complement activation (Szebeni, 2005).  
Symptoms of CARPA are the same as seen in common allergy or classical type I Ig-E-
mediated reactions, while others are unique to complement activation. The most 
important distinguishing feature of CARPA is the lack of presensitization and 
reinforcement, i.e., the reaction arises at the first exposure to the drug and then it may 
lessen or disappear, rather than increases upon later treatement (Szebeni, 2005). The 
increased awareness of (CARPA) is also reflected by the fact that testing for complement 
activation in vitro and/or in vivo has become one of the immuno-toxicology tests 
recommended by the US food and Drug Administration (FDA) that may be useful to 
identify the pseudoallergy potential of drugs, when needed (Szebeni, 2005). 
  
Perhaps a good example of CARPA is paclitaxel (Taxol), one of the most widely used 
anticancer drugs today. Taxol is a lipophilic drug which is dissolved in cremophor EL to 
induce solubility upon administration. Taxol is a natural product that shows clinical 
antitumour activity against some otherwise nonresponsive solid tumours (Slichenmyer & 
Von Hoff, 1991; Gregory & Delisa, 1993). With its unique mechanism of action as a 
stabilizer of tubulin polymerization, Taxol has become an important agent in 
chemotherapy (Szebeni et al., 1998).  Taxol formulation is known to cause an unusual 
hypersensitivity reaction in about 2-7% of patients, charecterized by dyspnea, flushing, 
rash, chest pain, tachycardia, hypotension, angiodema, and generalized urticaria 
(Rowinsky et al., 1992; 1993a; 1993b; 1993c; 1994; Sharma et al., 1993). The 
mechanism of induction of hypersensitivity reactions in response to Taxol administration 
has been linked to complement activation caused by its vehicle, i.e. CrEL (Szebeni et al., 
1998; Kessel et al., 1995).  Complement activation by Taxol or its vehicle may provide 
an explanation for the above anomaly in as much as it results in the production of 
anaphylatoxins (C3a and C5a), which, directly and through various secondary mediators 
can cause almost all symptoms of immediate hypersensitivity reactions (Hugli; 1984, 
Marceau et al., 1987; Mousli et al., 1992). In addition, complement activation explains 
the symptoms, which are uncommon with IgE-mediated allergy, such as the pulmonary 
infiltration (Ramanathan et al., 1996), hypertension (Nannan Panday et al., 1997) and 
severe cardiac arrhythmias (Laher & Karp, 1997).  
 
 
 
 
  
1.2.1 Non-ionic polymers  
In recent years the administration of several types of ethylene oxide (EO)–based nonionic 
surfactants, such as cremophor EL (CrEL) (as mentioned earlier) and poloxamers, has 
been generally used in parenteral drug delivery (Wang & Hanson, 1987; Eisenman & 
Bauer, 1995; Botempo, 1997; Nema et al., 1997; Soderlind et al., 2003). Present studies 
have demonstrated that cremophor EL (Szebeni et al., 1998) and block copolymers of 
poloxamer 188 (Moghimi et al., 2004) can induce hypersensitivity reactions. Those 
reactions are believed to arise as a result of complement activation-related pseudoallergy 
(CARPA).  
Poloxamers are a family of non-ionic surfactants composed of a central polypropylene 
oxide chain flanked at either side by a polyethylene oxide segment, thus forming an ABA 
block co-polymer structure (Moghimi & Hunter, 2000). Among the members of the 
poloxamer family, poloxamer 188 and 407 have found many applications in experimental 
and therapeutic medicine. For example, poloxamer 188 has been used in the development 
of fluorocarbon-based artificial blood substitutes (e.g., Fluosol-DA) (Vercellotti et al., 
1982). Poloxamer 407 at a concentration of 250 mg/ml can form a thermoreversible gel; 
the polymer is in aqueous solution at temperatures below 5 °C, but will gel at higher 
temperatures due to micellization and micelle entangelements (Cabana et al., 1997). As a 
result of its thermo-gelation properties, poloxamer 407 was recently used for reversible 
occlusions during percutaneous endovascular procedures (Poloxamer 407 forms a gel in 
concentrations above 200 mg/ml at 37 
0
C) (Raymond et al., 2004). Adverse reactions to 
poloxamers have also been noted, which again may be linked to complement activation. 
For example, infusion of Fluosol-DA into rabbits and dogs has been associated with 
transient, profound haemodynamic collapse accompanied by leukopenia and 
  
thrombocytopenia (Vercellotti et al., 1982; Faithfull & Cain, 1988). And the effects were 
reproducible following administration of relevant quantities of poloxamer 188 
(Vercellotti et al., 1982). In addition, poloxamer 188 was capable of activating 
complement in rabbit plasma via the alternative pathway (Vercellotti et al., 1982). In a 
clinical study, symptoms of complement activation related pseudoallergy were also 
reported in up to 30% of patients receiving Fluosol-DA as an adjunct to radiation 
treatment for advanced squamous tumours of the head and neck (Lustig et al., 1989).  
Recently, Moghimi et al demonstrated that both poloxamer 188 (at sub-micellar 
concentrations) and 407 (in micellar form) can activate human complement via calcium-
sensitive as well as alternative pathways (CMC of poloxamer 188 at 37 
o
C was 24-32 
mg/ml) (Moghimi et al., 2004). Poloxamer-mediated complement activation, however, is 
an intrinsic property of the polymer, and is independent of the degree of sample 
polydispersity or the presence of trace organic volatile (Moghimi et al., 2004). The 
mechanisms of poloxamer-mediated complement activation are still poorly understood, 
but activation of the alternative pathway may be related to inhibition of factors H and I. 
However, direct interaction between poloxamer and C3 or C4, which could lead to 
generation of products resembling activated C3 and C4 is unlikely, since complement 
activation by poloxamer was totally abolished in the absence of sCR1, an inhibitor of 
C3/C5 convertases (Moghimi et al., 2004).  
Quasi-elastic light scattering studies have recently confirmed poloxamers favourably 
interact with both HDL and LDL (Moghimi et al., 2004). For example, poloxamer 188 
caused a slight but significant increase in the hydrodynamic size of human HDL particles. 
The hydrodynamic size distributionof HDL and LDL were in agreement with their 
expected size (8-11 nm for HDL and 20-30 nm for LDL). Remarkably, the presence of 
  
poloxamer 188 generated two distinct populations of particles from LDL; one population 
of particles of 10-20 nm in size and a second population with particles in the range of 30-
50 nm (Moghimi et al., 2004). It is not clear whether these structures can activate 
complement, but elevation of serum HDL and LDL levels significantly reduced 
poloxamer 188-mediated rises of SC5b-9 (Moghimi et al., 2004). These observations are 
in line with the reported low incidence of poloxamer-mediated hypersensitivity reactions 
in subjects with abnormal or elevated lipid profiles (Vercellotti et al., 1982; Kent et al., 
1990). On basis of these studies it is imperative to examine possible regulatory and 
modulatory roles of lipoproteins and apolipoproteins on complement system during 
health and chronic inflammatory conditions.  
 
1.2.2 Polyethylene Glycol 
Poly(ethylene glycol) or PEG is a neutral, hydrophilic polyether which exhibits little 
reactivity unless modified with functional groups. PEG has a simple molecular structure, 
OH–(CH2–CH2–O)n–H, it is made from ethylene oxide and is similar to some non-ionic 
detergents. PEG and polyethylene oxide (PEO) are polymers that have an identical 
structure except for chain length and end groups, and are the most commercially 
important polyethers. PEG refers to the polymer with molecular weight less than 50,000 
(a condensation polymer made from ethylene glycol), while polyethylene oxide is used 
for higher molecular weights (an addition polymer). PEG is a water-soluble polymer used 
to solubilize proteins and is biologically inert and considered not toxic (Borgens & Shi, 
2000; Jumaa et al., 2002). 
PEG has many uses and applications including those related to its use as a non-toxic, 
non-immunogenic lubricant or carrier in pharmaceutical formulations. PEG has been 
  
widely used in parenteral drug delivery. Jumaa et al., (2002) have used PEG in parenteral 
lipid emulsions as targeting systems for poorly water-soluble drugs. Choe et al. (2004) 
have found that branching of the PEG allowed greater loading of the active drug when 
administrated parenterally. Also, PEG has been used in long-circulating parenteral 
emulsions (Reddy & Venkateswarlu, 2005). PEGylation of therapeutic proteins reduces 
renal clearance rates and protects from proteolytic and other degradation often resulting 
in enhanced medical efficacy. Other benefits of PEGylation may include improved 
physical and thermal stability, as well as solubility. The latter is particularly important 
with regard to biopharmaceutical formulation and delivery (Fee & Alstine, 2006). PEG 
has been used to fuse the membrane of numerous cells in culture, producing giant 
multinucleated ones (Pontecorvo, 1975). Moreover, PEG precipitation is the basis for 
several techniques for the detection and measurement of circulating immune complexes 
and considered widely safe (Hyun et al., 1992; Soltis et al., 1983; Rayner et al., 1981). 
Recently, Borgens and Shi, (2000) reported that a 2-min application of PEG parenterally 
led to immediate recovery from spinal cord injury through molecular repair of nerve 
membranes in animals. To date, there are no studies exploring the margins of safety of 
PEG after parenteral administration. This work will examine the toxicity of different 
grades of PEG and their possible mechanism of activating human immune responses.  
 
1.2.3 Stealth liposomes 
Liposomes are vesicular structures that form on hydration of dry phospholipids above 
their transition temperature and that are classified on the basis of their size and number of 
bilayers (Moghimi et al., 2005). Drug molecules can be either entrapped in the aqueous 
space or intercalated into the lipid bilayer of liposomes, depending on the physiochemical 
  
characteristics of the drug. Recently, a lot of work has been focused on developing long 
circulating vehicles with size within the nanoscale range. Surface stabilization of 
nanoparticles and liposomes with a range of non-ionic surfactants or polymeric 
macromolecules has been one of the most successful approaches for keeping the particles 
in the blood for prolonged periods of time (Moghimi et al., 2001; Moghimi & Hunter, 
2000; Monfardini & Veronese, 1998). Surface enrichment of nanocarriers with non-ionic 
surfactants can be achieved by physical adsorption, incorporation during production of 
the carriers or by covalent attachment to any reactive surface groups (Moghimi & 
Szebeni, 2003). The presence of such surfactants on the surface of the particle strongly 
reduces interparticulate attractive Van der Waals forces while increasing the repulsive 
barrier between two approaching particles. This steric mechanism of stabilization 
involves an elastic as well as an osmotic contribution (discussed in details by Moghimi & 
Szebeni, 2003) (deGennes, 1987; Moghimi et al., 1993; Lasic et al., 1991). 
 It is generally known now that the macrophage-resistant property of polymer-grafted 
particles is due to suppression of surface opsonization by serum plasma proteins 
(Moghimi et al., 2001 and 1993). Therefore, it is not surprising that polymer-grafted 
particles exhibit prolonged residency times in the blood. Contradictingly, studies have 
shown that opsonization of sterically protected particles can occur efficiently. One 
example is complement activation by long-circulating liposomes, which results in surface 
opsonization with C3b and iC3b (Szebeni, et al., 2000; 2002; 2001).  
Following intravenous injection, liposomes and nanoparticles are cleared rapidly from the 
blood by the RES, particularly the hepatic Kupffer cell (Moghimi et al., 2001). 
Conversely, stealth liposomes circulate for prolonged hours; reported half-lives vary from 
2 to 24 h in mice and rats and can be as high as 45 h in humans depending on the particle 
  
size and the characteristics of the coating polymer (Moghimi et al., 2001; Allen et al., 
1991; Gabizon & Muggia, 1998). However, a rapid hepatic and splenic deposition of a 
fraction of the administered long circulating liposomes has been reported. For example, 
stealth liposomes (e.g. PEGylated vesicles) have been administered in doses ranging from 
0.1 to 400 µmol/kg body weight with reported hepatic and splenic sequestration of 10-15 
nmol/kg within the first hour of injection (Laverman et al., 2000; 2001; Allen et al., 
1991). Recently, biophysical studies have established that the bilayer concentration of 
mPEG-lipid controls conformation of the surface exposed mPEG chains (Triosh et al., 
1998). For example, with incorporation of 5-7 mol% mPEG2000-phospholipid into 
liposomal bilayer, the exposed mPEG chains predominantly assume a “mushroom-brush 
transition” conformation, whereas at concentrations of up to 4 mol% mPEG projections 
are in a “non-overlapped mushroom” regime (Triosh et al., 1998). It is also known that 
particles with surface exposed mPEG2000-5000 chains in predominantly “mushroom 
brush” conformation are highly resistant to clearance by quiescent macrophages, whereas 
particles with “non-overlapped mushroom” display remain susceptible to ingestion by 
phagocytic cells (Gbadamosi et al., 2002; Moghimi & Szebeni, 2003).  
 
1.2.4 Carbon nanotubes  
The complement system is an important effector arm of both innate and acquired 
immunity and can be triggered by three separate pathways: the classical, the lectin and 
the alternative pathway (Lambris et al., 2008). Classical pathway activation is triggered 
when the hexameric C1q subcomponent of C1 binds to an activator. This interaction 
induces a conformational change within the C1 complex resulting in conversion of the 
zymogen C1s subcomponent into an active proteolytic enzyme that cleaves C4 (Lambris 
  
et al., 2008). The lectin pathway of complement activation is initiated by the binding of 
mannan-binding lectin (MBL) or ficolins to an activator leading to activation of MBL-
associated serine proteases (MASPs) (MASP-1, -2, -3) and a smaller protein sMAP 
(Map19) (Matsushita et al., 2000; Vorup-Jensen et al., 2000). Among these proteases, 
MASP-2 has an established role in cleaving and activating C4 (Vorup-Jensen et al., 
2000). Conversely, the alternative pathway is stimulated by the spontaneous cleavage of 
thioester bond in C3 or when the internal thioester bond in the α-chain of C3b undergoes 
nucleophilic attack in the presence of a foreign surface structure rich in nucleophilic 
groups (particularly hydroxyl- and amino-rich surfaces (Lambris et al., 2008; Toda et al., 
2008).  
Carbon nanotubes have received substantial attention as promising materials for a wide 
range of experimental diagnostic and therapeutic applications following intravenous 
injection (Lacerda et al., 2006; Liu et al., 2007 and 2008). However, the interaction 
between carbon nanotubes and the complement system has not received much attention. 
An isolated study with non-functionalized high pressure carbon monoxide single-walled 
carbon nanotubes (HIPco SWNTs) and double-walled carbon nanotubes (DWNTs) has 
revealed nanotube-mediated complement activation in human serum (Andersson et al., 
2002). Remarkably, activation pathway was dependent on nanotube morphology; while 
both hydrophobic HIPco SWNTs and DWNTs activated human complement system via 
the classical pathway through exclusive surface adsorption of C1q, DWNTs further 
activated complement through the alternative pathway (Andersson et al., 2002). In order 
to enhance nanotube stability in the blood and suppress their rapid clearance by kupffer 
cells and splenic macrophages following intravenous injection, SWNTs were surface 
modified with PEG phospholipids (Liu et al., 2007). However, it has now emerged that 
  
PEGylated nanoparticles are still capable of activating complement (Salvador-Morales, et 
al., 2006). This study will attempt to focus more on the interaction of these carbon 
nanotubes with the complement system.   
 
1.3 Fate of intravenously injected nanoparticles  
Colloidal carriers in the form of emulsions, liposomes or nanoparticles can have utility 
for the delivery of drugs to the systemic circulation. Normally, a foreign particle upon 
intravenous injection will be coated by blood components (opsonisation) and rendered 
‘visible’ to the defence system of the body; the reticuloendothelial system (RES) 
(Göppert & Müller, 2005), which is extremely efficient at removing particles recognised 
as foreign. As a consequence, these systems are very efficient in targeting of drugs or 
diagnostic agents to the RES and briefly reviewed below (Moghimi et al., 2001 and 
2005). These processes are however controlled by particle size and surface 
characteristics.   
Macrophages are widely distributed and strategically placed in many tissues of the body 
to recognize and clear, altered and
 
senescent cells, invading particulates, as well as 
macromolecular
 
ligands via a multitude of specialized plasma membrane  receptors
 
(Gordon et al., 1986).  
This propensity of macrophages for endocytosis/phagocytosis of foreign particles in the 
past has provided an opportunity for the efficient delivery of therapeutic agents to these 
cells in the treatment
 
of certain infectious diseases. This was achieved based on targeting 
pathogenesis or microbial
 
diseases in macrophages (Agrawal & Gupta, 2000) with
 
the aid 
of colloidal drug delivery systems usually in the form
 
of liposomes, polymeric 
nanospheres, micelles, and oil-in-water
 
emulsions (Moghimi et al., 2001). Apart from
 
  
therapeutic goals, colloidal carriers have proved to be useful
 
for diagnostic purposes, for 
example, to assess macrophage phagocytic
 
and clearance functions. Similarly, particulate 
colloids tagged
 
with a suitable radiopharmaceutical or contrast agent were shown
 
to be 
helpful for imaging certain pathologies e.g., deep-seated tumors, not via targeting but 
through macrophage loading (Kostarelos & Emfietzoglou, 1999). 
The rapid recognition and sequestration of intravenously injected colloidal carriers such 
as nanospheres from the blood by RES (hepatic midzonal and periportal kupffer
 
cells) is 
problematic for efficient targeting of drug carriers
 
or diagnostic agents to a desired 
macrophage population e.g.,
 
splenic red pulp macrophages as well as to nonmacrophage 
sites (Moghimi et al., 2001; Göppert & Müller, 2005).  
As a result, there has been a growing interest in the engineering
 
of long-circulating 
colloidal carrier systems that upon intravenous injection avoid rapid recognition by RES 
and adequately remain in blood circulation.  
 
1.4 The influence of surface PEGylation on complement activation 
Liposomes are increasingly used in medicine for targeted or controlled release of various 
drugs and diagnostic agents. However, studies have shown that these liposomes can cause 
hypersensitivity reactions with symptoms corresponding to CARPA. The frequency of 
HSRs to liposomal drugs shows large variation between 3 and 45% (Szebeni et al., 1998 
and 2001). Complement activation by liposomes has been analysed in a great number of 
studies. The results are somehow complex, as variations in liposome structure and/or 
other experimental conditions might result in huge difference in the extent, kinetics and 
the pathway of activation (Szebeni et al., 1998 and 2001).  
  
Bradley et al., (1998) have examined the ability of PEG-lipids to inhibit the in vitro 
activation of complement in human serum. 100 nm liposomes composed of egg 
phosphatidylcholine, cholesterol and cardiolipin (35:45:20 molar ratio) were shown to 
activate complement system resulting in 80% complement consumption at liposome 
concentrations above 1 mM. Conversely, these investigators suggested that complement 
activation can be virtually abolished by incorporating 5-7.5 mol% of PE-mPEG2000 
(phosphatidylethanolamine methoxypoly(ethylene glycol 2000)) into the liposomal 
bilayer. However, Moghimi and Szebeni (2003) in their review suggested that a closer 
look at the above study reveals that the inhibitory effect of the mPEG-lipid on 
complement activation is highly dependent on the liposome concentration used in the 
assay. Complement consumption was significantly above the baseline at liposome 
concentrations above 4 mM (Bradley et al, 1998). For instance, incubation of 4, 8 and 15 
mM of liposomes (containing 5 mol% PE-mPEG2000) with human serum for 30 min led to 
20, 35 and 40% complement consumption, respectively. This claim was supported by 
series of studies by Szebeni who proved that the inclusion of 5% PE-mPEG2000 into 
liposomal bilayer may not be sufficient to prevent complement activation. For example, 
incubation of Doxil
®
 (a PEGylated liposome with encapsulated anticancer agent; 
doxorubicin with a clinical dose calculated on the basis of patient weight and surface area 
and infused over a few hours) with 10 different normal human sera led to significant 
activation of complement levels over control (phosphate buffer) in 7 sera (Szebeni et al., 
2000). Doxil
® 
was effective at concentration as low as 0.4 mg lipid/ml in activating 
complement. Therefore, Doxil
® 
can cause significant complement activation in vitro, 
although the extent of this activation may substantially vary in different individuals.  
  
Recent study by Mosqueira et al (2001) has also demonstrated that surface modification 
on polymeric nanocapsules with PE.G., regardless of the PEG chain length or density, 
cannot totally prevent complement activation. However, longer chains PEG were more 
effective in suppressing complement activation (Mosqueira et al., 2001). 
 
1.5 Opsonization and phagocytosis 
Opsonization is a process by which the surface of protein particles are altered so that they 
are more readily and more efficiently engulfed and removed by macrophages of the RES 
(Donald & Nicholas, 2006).  
Thus, the clearance of opsonised particles by macrophages involves binding to various 
receptors such as Fc receptors, complement receptors, engulfment by lamellipodia that 
project from the cell surface, internalization by zipper process and subsequent delivery of 
the particles to acidic endosomes and finally to lysosomes for degradation (Moghimi et 
al., 2001).  
Examples of opsonic molecules includes various subclasses of immunoglobulins, 
complement proteins like C1q and C3 fragments (C3b and iC3b), apolipoprotein, von 
willebrand factor, thrombospondin, fibronectin and mannose-binding protein (Szebeni, 
1998). There are five known types of complement receptors (CR1, CR2, CR3, CR4 and 
C1qR), expressed on macrophage, monocytes and leukocytes. Nanoparticles (e.g., 
liposomes) can be intentionally opsonised with non-specific and monoclonal antibodies 
in order to enhance their recognition and clearance by macrophages via their Fc receptors 
both in vivo and in vitro (Rogers & Basu, 2005).  
Moghimi and Patel (1998) have also found that rat serum contains two proteins which 
suppress recognition of liposomes by kupffer cells. These proteins are classified as 
  
dysopsonins. Dysopsonins act by decreasing opsonisation and/or inactivating liposome-
bound opsonins. Therefore, a balance between opsonins and dysopsonins could regulate 
the rate and quantity of liposome clearance from the blood by kupffer cells. These 
dysopsonins and their mode of action need to be identified, as they can be used in 
designing long circulatory systems.  
It is crucial to note that complement activation can lead to cleavage of C3 into C3b, iC3b 
and C3a. However, production of C3a is thought to cause anaphylactic reaction in some 
individuals (Hunter & Moghimi, 2002).  
 
1.6 Over view of the complement system 
When the “immune system” is mentioned, attention is focused on the antibodies and B- 
and T-lymphocytes which guard human body against pathogens. Complement system, on 
the other hand, is a very important system in both acquired and innate immunity. The 
complement system consists of approximately 30 molecules consisting nearly 10% of the 
total serum protein, and forming one of the major defence systems of the body. The 
functions of the system include control of inflammatory reactions, clearance of immune 
complexes, cellular activation and anti-microbial defence. The system also plays a role in 
the development of the immune response and is a major effector system in autoimmune 
and hypersensitivity reactions. The ultimate result of complement activation is the 
formation of membrane attacking complex (MAC). MAC is a large complex that induces 
a pore in the membrane of the invading microorganisms. This results in the loss of 
membrane integrity and destroys the pathogen ability to control the concentration of the 
intracellular metabolites (Woodle, 1998). Activation of the complement pathways occurs 
via two enzyme cascades in which active components enzymatically cleave the following 
  
component(s), the trigger being either antigen-antibody complexes (classical and lectin 
pathways) or a variety of surfaces favouring alternative-pathway activation (Fig. 1.1).  
 
1.6.1 The classical pathway 
The classical pathway of activation of the complement system is a group of blood 
proteins that mediate the specific antibody response. It is triggered by antigen-bound 
antibody molecules. Binding of a specific part of the antibody molecule to the C1 
component initiates this pathway. The classical pathway is triggered by activation of the 
C1-complex, which consists of one molecule C1q and two molecules C1r and C1s, either 
by C1q’s binding to antibodies from classes M and G, complexed with antigens, or by the 
binding C1q to the surface of the pathogen. C1q possesses no intrinsic activity, but when 
any of several activators bind to the C1q subcomponent of C1, the homologous C1r and 
C1s subcomponents are converted into catalytically active species, namel C1r and C1s 
triggering the first step of the classical pathway of complement activation. Then they 
cleave C1s (another serine protease). The C1-complex now binds to and splits C2 and C4, 
producing C2a and C4b. C4b and C2a bind to form C3-convertase (C4b2a complex) (Fig. 
1.1). production of C3-convertase signals the end of the classical pathway, but cleavage 
of C3 by the enzyme leads to the start of the alternative pathway.  
1.6.2 The alternative pathway 
The alternative pathway of the complement system is a humoral component of the 
immune system's natural defense against infections which can operate without antibody 
participation. The alternative pathway is triggered by C3 hydrolysis directly on the 
  
surface of pathogen. In this pathway, C3 split into C3a and C3b. Some of the C3b is 
bound to the pathogen where it will bind to factor B, this complex will then be cleaved by 
factor D into Ba and the alternative pathway C3-convertase, Bb. After hydrolysis of C3, 
C3b complexes to become C3b2a3b, which cleaves C5 into C5a and C5b. C5a and C3a 
initiate inflammatory reactions because they are both chemotactic factors for phagocytes 
and anaphylatoxins that cause mast cells to degranulate. C5b with C6, C7, C8 and C9 
(C5b6789) complex to form the membrane attack complex (MAC) which is inserted into 
the cell membrane (bunches a hole) to initiate cell lysis.  
1.6.3 The lectin pathway 
This pathway is activated by binding mannan-binding lectin to mannose residues on the 
pathogen surface, which activates the mannan-binding lectin (MBL)-associated serine 
proteases, MASP-1, MASP-2, MASP-3, which can then split C4 and C2 into C4b and 
C2b. C4b and C2b then bind together to form C3-convertase, as in the classical pathway. 
  
 
 
 
 
 
 
  
 
Fig. 1.1 Complement activation pathways. The complement system can be triggered by 
three separate pathways: the classical, the lectin and the alternative pathways. Classical 
pathway activation is triggered when the hexameric C1q subcomponent of C1 binds to an 
activator (e.g., immunocomplexes or a surface). This induces a conformational change 
within the C1 complex resulting in conversion of the zymogen C1s subcomponent into an 
active proteloytic enzyme that subsequently activates the C1s subcomponent. Activation of 
the lectin pathway proceeds following the binding of mannose binding lectin (MBL) or 
ficolins to an activator, leading to conversion of their MBL-associated serine proteases 
(MASPs)-1,  -2 , -3 zymogens to active proteloytic enzymes. Activated C1s of the classical 
pathway and the MASP-2 of the lectin pathway both cleave the C4 protein; this in turn 
activates C2 thus leading to subsequent generation of the classical/lectin pathway C3 
convertase, C4b2a. Alternative pathway activation proceeds following spontaneous and 
induced C3 hydrolysis. This subsequently generates alternative pathway C3 convertases 
(C3bBb) through mediations of factors B and D. Three consequences subsequently arise 
from complement activation. These include priming of the activator surface by opsonic 
complement fragments (e.g., C3b, iC3b) for engulfment by phagocytes, generation of 
anaphylatoxins and chemoattractants (e.g., C3a, C5a) and formation of the membrane attack 
complex (C5b-9) through C5 convertases. Key negative regulators (C4bp, factor I, factor H, 
S protein) are also shown. Anaphylatoxin C3a is very short lived and in serum is cleaved 
rapidly to the more stable C3a-desArg. 
 
  
 
1.7    Aims of the project 
This study was undertaken to examine the hypersensitivity reactions caused by 
nanomedicines based on complement activation. The aims of the project were generally 
as follows: 
 
• To Investigate and identify which structural features of phospholipid-mPEG 
conjugate are responsible for complement activation, and to design a novel 
conjugate that when incorporated to liposomes, suppress complement activation.  
• To examine whether the elevation of human serum lipoproteins levels can exert a 
protective role against cholesterol-rich liposome-mediated complement activation 
both in vitro and in vivo. 
• To study the safety of different molecular weights of PEG regarding 
hypersensitivity reactions. This included full understanding of possible activation 
pathways, effect of molecular weights, and different molar concentrations. 
• To investigate the interaction of amino-PEG5000- 
distearoylphosphatidylethanolamine (amino-PEG5000-DSPE) and 
methoxy(MeO)PEG5000-DSPE functionalized SWNTs with the complement 
system both in vitro and in vivo. 
 
 
 
 
 
  
 
 
 
 
 
Chapter two: 
 
Methylation of the phosphate oxygen moiety of 
phospholipid-methoxy(polyethylene glycol) conjugate 
prevents PEGylated liposome-mediated complement 
activation and anaphylatoxin production 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2.1 Introduction 
The rapid sequestration of intravenously injected liposomes by macrophages in 
contact with blood is problematic for efficient targeting of particulate nanocarriers to 
non-macrophage cells at pathological sites (Moghimi et al., 2001). Surface 
manipulation of liposomes with methoxy(polyethylene glycol), (mPEG), affords 
control over vesicle interaction and fate within biological systems (Moghimi et al., 
2001 and 2005). mPEG grafting suppresses liposome-macrophage interaction either 
directly or through reduced surface opsonization or both (Moghimi et al., 2001). The 
extent of vesicle opsonization and vesicle-macrophage interactions are controlled by 
mPEG chain length and surface density. For example, vesicles bearing 5–7 mol% of 
phospholipid-mPEG2000 conjugate are usually resistant towards macrophage 
recognition. With shorter mPEG chain length (eg, 350-1000 Da), bilayer enrichment 
with 10–25 mol% phospholipid-mPEG is necessary in order to avoid rapid 
macrophage phagocytosis (Moghimi et al., 2001).  As a result of such surface 
manipulation strategies with mPEG the engineered vesicles exhibit prolonged 
residency time in the blood circulation and can escape from the vasculature. Vesicle 
extravasation, however, is restricted to capillaries with open fenestrations or sites 
where the endothelial barrier of blood capillaries is perturbed by inflammatory 
processes or by dysregulated angiogenesis (Moghimi et al., 2001). Indeed, the first 
generation of long-circulating PEGylated liposomes with encapsulated doxorubicin 
are already on the USA and European markets for management and treatment of 
AIDS-related Kaposi’s sarcoma, refractory ovarian cancer and metastatic breast 
cancer (Allen & Cullis, 2004).  
  
One of the most frequently encountered clinical problems following infusion of 
PEGylated liposomes into certain subjects is initiation of non-IgE-mediated 
hypersensitivity reactions, which includes symptoms of cardiopulmonary distress, 
such as dyspnea, tachypnea, tachycardia, chest pain, hypertension, and hypotension 
(Uziely et al., 1995; Alberts & Garcia, 1997; Chanan-Khan et al., 2003). These 
pseudoallergic reactions are strongly believed to arise through rapid production of 
anaphylatoxins C3a and C5a via complement activation leading to the release of 
TXA2 and other anaphylatoxin-derived mediators (Chanan-Khan et al., 2003; Szebeni et 
al., 2000). In spite of the general view that surface camouflaging with mPEG should 
dramatically suppress blood opsonization processes, liposomes bearing phospholipid-
mPEG conjugates in their bilayer surprisingly activate the complement system and fix 
complement proteins (Szebeni et al., 2000; Moghimi & Szebeni, 2003). However, 
complement fixation seems to play a minor role in macrophage clearance of 
PEGylated vesicles via complement receptors since PEGylated liposomes remain 
intact in the blood pool for prolonged periods of time (Szebeni et al., 2000; Moghimi 
& Szebeni, 2003). Interestingly, liposomes of the same size distribution and bilayer 
composition as their PEGylated counterparts but without the phospholipid-mPEG 
conjugates rarely activate human complement system, and hence do not generate 
anaphylatoxin. In view of numerous medical applications for PEGylated liposomes 
and the clinical importance of the observed complement-mediated hypersensitivity 
reactions that can lead to anaphylactoid shock and cardiac anaphylaxis (Szebeni et al., 
2006), this study sought to investigate and identify which structural features of the 
phospholipid-mPEG conjugate are responsible for PEGylated liposome-induced 
complement activation in human sera. The efforts were particularly focused on design 
  
and synthesis of novel lipid-mPEG conjugates where the phospholipid moiety of the 
conjugates is made from pro-drug ether lipids, as a first critical step towards 
development of safer long circulating vesicles for drug release at pathological sites 
with elevated sPLA2 activity (Andresen et al., 2005a and b). Accordingly, this study has 
designed PEGylated liposomes that do not activate complement both in vitro and in 
vivo. 
 
2.2  Materials and methods 
      2.2.1 Materials 
DPPE-mPEG350 and DPPE-mPEG2000 were from Avanti Polar Lipids Inc. 
(Alabaster, AL, USA).  
DPPC, DPPG, cholesterol, ELISA kits for plasma TXB2, and all other reagents were 
obtained from Sigma Chemical Company (Poole, UK). 
      C1q-depleted human serum, purified human C1q, and enzyme-linked immunosorbent 
assay kits (SC5b-9, C4d, Bb and C3a-desarg) were from Quidel Corporation (San 
Diego, CA, USA).  
Mouse anti rat CD11b (azide free, clone MRC OX-42) and polyclonal mouse IgG        
were from Serotec (Oxford, UK).  
 Mouse monoclonal antibody against human complement factor B was obtained from       
Antibody Shop A/S (Gentofte, Denmark).  
Near monodisperse polyethylene glycols (PEGs), Mw = 400 and 1960 Da, were from 
Fluka (UK). 
2.2.2 Methods 
2.2.2.1 Synthesis of phospholipid-mPEG conjugates 
  
The synthesis of 1-O-DPPE- (Me)mPEG350 (compound 5) and 1-O-DPPE-
mPEG350 (compound 6) was carried out using (R)-O-benzyl glycidol as a convenient 
starting material as described by (Andresen et al., 2004), Fig. 2.1. The synthetic 
approach to the two ether lipids involves the synthesis of compound 3 (Fig. 2.1a), 
which is readily formed from compound 1 on multi-gram scale (Andresen et al., 
2004). Preparation of the protected phosphatidylethanolamine 4 was carried out using 
methyl dichlorophosphate and TMP as base. Deprotection followed by coupling with 
mPEG350 gave the desired 1-O-DPPE-(Me)mPEG350 (5, termed Conj-B). Conj-B 
was converted to 1-O-DPPE-mPEG350 (6, termed Conj-A). The two conjugates were 
analyzed by 
1
H-NMR (300 MHz), 
13
C-NMR (75 MHz), and HPLC using evaporative 
light scattering detector (Andresen et al., 2004).  
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Fig. 2.1. Synthetic pathway and chemical structures of pro-drug ether lipid-mPEG 
conjugates (Conj-A and Conj-B). Synthetic steps are as follows: (step a): hexadecanol 
(C16H33OH), NaH, tetrahydrofurane (THF), dimethylformamide (DMF), 16h, 80°C, then 
palmitoyl chloride, pyridine, hexane, 16h, room temperature; (step b): H2, Pd/C, ethyl 
acetate, 1.5h, room temperature; (step c): methyl dichlorophosphate, TMP, toluene, 16h, 
room temperature, then N-BOC-ethanolamine, TMP, 24h, room temperature; (step d): 
TFA, MeOH, CH2Cl2, 0.5h, 0°C, then mPEG350 N-succinimidecarbonate, Et3N, CHCl3, 
2h, 40°C; (step e): NaI, 2-butanone, 2h, 75°C (Andresen et al., 2005b). 
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2.2.2.2  Preparation and characterization of liposomes and phospholipids-
mPEG micelles 
Liposomes were composed of either DPPC or 1-O-DPPC with or without various 
amounts of different phospholipid-mPEG conjugates. Some DPPC preparations contained 
5–20 mol% DPPG. Generally, liposomes were prepared by hydrating the dried lipid film 
with 10 mM PBS, pH 7.2, then extruded through polycarbonate Nuclopore filters with 
pore diameters of 200 nm using a high-pressure extruder.  
The critical micelle concentration of selected phospholipids-mPEG conjugates was 
determined by measuring pyrene solubilization. The formation of micelles is associated 
with pyrene solubilization, which is monitored by measuring the solution fluorescence.  
Liposome and phospholipids-mPEG micelle size distribution was determined by laser 
light scattering using a Malvern Zetasizer 3000 (Malvern Instruments, Malvern, UK) at 
25 °C (Moghimi & Patel, 2002).  
 
2.2.2.3  Collection and treatment of serum specimens 
Blood was drawn from healthy male volunteers according to approved local protocols. 
Blood was allowed to clot at room temperature and serum was prepared, aliquoted and 
stored at –80 °C. Serum samples were thawed and kept at 4 °C before incubation with 
test reagents. 
Commercially available C1q-depleted human serum was further depleted from Factor B. 
This was achieved by incubating serum with mouse monoclonal anti-complement factor 
B antibodies coupled to activated CNBr-sepharose (Klint et al., 2000). Depletion of factor 
B was monitored by measuring zymosan-induced generation of serum complement 
activation product SC5b-9 (see below). 
  
 
2.2.2.4  Assay of in vitro complement activation 
To measure complement activation in vitro, we determined the liposome- micelle-, and 
PEG-induced rise of serum complement activation product SC5b-9, C4d, Bb and C3a-
desarg formation, using respective Quidel’s enzyme-linked immunosorbent assay kits 
according to the manufacturer’s protocol (Szebeni et al., 2000; Savay et al., 2002; 
Szebeni et al., 1997). Because of substantial biological variation in serum levels of 
complement proteins and the large number of positive and negative feedback interactions, 
this study monitored generation of complement activation products in sera of 5 healthy 
individuals separately. The reaction was started by adding the required quantity of 
liposomes, micelles, PEGs, and other required additives to undiluted serum (liposome to 
serum volume ratio of 1:4) in Eppendorf tubes (in triplicate) in a shaking water bath at 37 
°C for 30 min, unless stated. The final incubation volume was 150 µl. Reactions were 
terminated by addition of ‘sample diluent’ provided with assay kit. SC5b-9 generation 
was also monitored in C1q-depleted human serum prior and after addition of 
physiological concentration of C1q (180 µg/ml). In some experiments, factor B was 
immunochemically depleted from C1q-depleted serum. Control incubations contained 10 
mM PBS (pH 7.2) for assessing background levels of SC5b-9, C4d, Bb, and C3a-desarg. 
Zymosan (5 mg/ml) was used as a positive control for complement activation.  
The efficacy of liposome treatments was established by comparison with baseline levels 
using paired t-test; correlations between two variables were analyzed by linear regression, 
and differences between groups (when necessary) were examined using ANOVA 
followed by multiple comparisons with Student-Newmann-Keuls test. 
  
  
2.2.2.5  Determination of complement hemolytic activity and TXB2 level in 
rat blood                             
Prior to liposome injection 1–1.5 ml blood was taken from the tail vein of male Wistar 
rats (310 ± 30 g) for both plasma and serum preparation to obtain the required baseline 
parameters. For plasma preparation, blood was collected in EDTA/0.25 mM 
indomethacin-containing tubes to prevent prostaglandin metabolism. Appropriate 
liposome formulations were injected intravenously (80 mg/Kg body weight in 0.5–1.0 
ml), bolus injection within 5 s, via the opposite tail vein. Further blood samples were 
taken at 8 and 60 min post liposome injection to obtain plasma and serum. Plasma TXB2 
levels were determined by following the procedures supplied with the ELISA kit. 
Undiluted serum was used to measure CH50 using sheep red blood cell hemolysis assay as 
discussed by Szebeni et al., (1994). 
 
2.3 Results and discussion  
2.3.1 Conjugate synthesis and rationale for liposome design 
One of the key structural features in mPEG-phospholipid conjugate is the presence of a 
net anionic charge localized on the phosphate oxygen moiety of the mPEG-phospholipid 
conjugate, which could be responsible for complement activation. This hypothesis is 
based on previous observations that small unilamellar neutral non-PEGylated liposomes 
(liposomes of similar composition to clinical formulation of PEGylated vesicles but 
without the phospholipid-mPEG conjugate) causes no or minimal activation of the human 
and pig complement system (Szebeni et al., 2000 and 2002). On the contrary, bilayer 
enrichment of non-PEGylated liposomes with dicetylphosphate or a variety of anionic 
phospholipids, regardless of their headgroup structure, induces complement activation in 
  
both human and animal sera (Szebeni et al., 2000; Moghimi & Szebeni 2003; Chonn et 
al., 1991; Devine et al., 1994; Bradley et al., 1998; Moghimi & Hunter, 2001). Therefore, 
this study synthesized two types of phospholipid-mPEG conjugates bearing different 
charges as demonstrated in Fig. 2.1. The key structural features of the first conjugate 
(Conj-A) mirrors PE-mPEG; a conjugate with a proven capability of prolonging the 
circulatory half-life of liposomes in the vasculature. Thus, the phosphate moiety of Conj-
A is anionic and its phosphodiester and amide linkage groups are the same as PE-mPEG. 
In the second conjugate (Conj-B), the phosphate oxygen is methylated to eliminate the 
net negative charge, thus yielding a nonionic species (Fig. 2.1). The mPEG segment of 
both Conj-A and -B are purposely short in length (7 ethylene glycol units, Mw = 350 
kDa) for better exposure of phosphodiester linkage and liposome surface to complement 
proteins, thus testing the validity of the proposed complement activation hypothesis.  
In contrast to classical phospholipid-mPEG conjugates, the phospholipid component of 
Conj-A and Conj-B bear a non-hydrolyzable ether bond in the 1-position (1-O-
phospholipid). This feature is not directly applicable to complement activation hypothesis 
but is essential for designing long-circulating multi-functional 1-O-phospholipid-based 
vesicles for efficient drug delivery and trigger release at selected non-macrophage 
pathological sites, which has an active interest. 1-O-phospholipids form highly stable 
liposomes with no hemotoxicity as demonstrated recently (Andresen et al., 2004; 
Moghimi & Patel, 2002). These vesicles also function as prodrugs; sPLA2 and its 
subtypes being the activating enzymes, and their levels are dramatically elevated in the 
interstitium of solid tumors as well as at various inflammatory sites (Andresen et al., 
2005a and b). sPLA2 not only act as a trigger resulting in the release of encapsulated 
cytotoxic drugs from pro-drug ether lipid liposomes, but also generates highly cytotoxic 
  
lysolipids that destabilizes plasma membrane of cancer cells as shown recently (Andresen 
et al., 2005a).  
This study incorporated 1-O-DPPE-mPEG conjugates (Conj-A and Conj-B) into DPPC 
liposomes, since the resultant vesicles are highly stable in serum, and in addition DPPC 
vesicles do not activate the human complement system (see below). Also, the bilayer of 
constructed vesicles is not enriched with cholesterol, since incorporation of cholesterol, 
particularly at above 30 mol%, is known to activate the human complement system via 
the classical pathway following binding of anti-cholesterol antibodies, which are 
abundant in most human sera (Alving et al., 1991). Indeed, cholesterol-rich liposomes 
have been shown to cause massive hemodynamic changes in pigs via complement 
activation (Szebeni et al., 2000). 
 
2.3.2 Liposome-mediated complement activation in vitro 
This study demonstrated complement activation in sera of a number of healthy subjects 
with liposomes containing an anionic phospholipid (DPPC:DPPG, mole ratio 9.5:0.5) by 
measuring the generation of the complement activation product SC5b-9, which is a 
sensitive and established  measure of the activation of the whole complement cascade 
(Szebeni et al., 2003), Fig. 2.2a. These observations are in line with previous reports 
(Szebeni et al., 2000; Chonn et al., 1991; Devine et al., 1994) suggesting that vesicles 
exhibiting a net negative charge, but not neutral DPPC vesicles, activate the human 
complement system. PEGylated liposomes also caused complement activation with 
significant rises of SC5b-9 levels over baseline, comparable to non-PEGylated 
DPPC:DPPG vesicles of the same size distribution in all tested sera (Fig. 2.2a). With 
Conj-A-containing (5 mol%) liposomes SC5b-9 generation proceeded on a time scale of 
  
minutes, also identical to DPPE-mPEG350-incorporated vesicles and reached plateau at 
around 15–20 min. Further, Conj-A-containing liposomes were effective in causing 
significant rises of SC5b-9 levels in serum at a final lipid concentration of 1 mg/ml, with 
a trend of reaching maximal efficacy at lipid concentrations of 3–4 mg/ml. As a control 
experiment, this study assessed SC5b-9 generation in serum following incorporation of 1-
O-DPPC (5 mol%) into DPPC vesicles as well as by pure 1-O-DPPC vesicles (Fig. 2.2b). 
Indeed, 1-O-DPPC was ineffective in raising serum SC5b-9 levels above the baseline, but 
bilayer enrichment of 1-O-DPPC vesicles with anionic phospholipid-mPEG conjugates 
raised serum SC5b-9 levels in a similar manner to PEGylated DPPC vesicles (Fig. 2.2b).  
Thus, complement activation, as reflected by increase in serum levels of SC5b-9, 
proceeds with anionic lipid-mPEG conjugate-incorporated liposomes independent of 
mPEG molecular weight (350 and 2000 kDa) or its conjugated lipid structure (DPPC or 
1-O-DPPC). 
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Fig. 2.2.a. Effect of liposomes on complement activation: SC5b-9 levels in sera of 5 
healthy subjects 30 min after liposome treatment (3 mg lipid/ml) at 37 °C. The values in 
the brackets represent lipid mole ratios. With the exception of neutral liposomes and 
viscles containing Conj-B, generated SC5b-9 levels were significantly higher than the 
background. P< 0.05. (n= 3).  
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Fig. 2.2.b. Effect of liposomes on complement activation: the effect of 1-O-DPPC 
bearing liposomes (70–110 nm) on SC5b-9 generation in serum of subject 5. 
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Fig. 2.2.c. Effect of liposomes on complement activation: the influence of lipid-mPEG 
conjugates (5 mol%) on DPPC liposome-mediated anaphylatoxin generation (C3a-
desarg) over time in serum of subject 1. Results are expressed in percentage of control 
baseline. With the exception of Conj-B, results were significantly different relative to 
control (P< 0.05). All liposomes were in 70-110 nm size range.  
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To further confirm the role of the anionic charge of the phosphate oxygen moiety in 
complement activation this study demonstrated rises in C3a-desarg levels in human 
serum over time (Fig. 2.2c). The rise of SC5b-9 levels in human sera remarkably 
correlates with C3a production, providing further evidence that the anionic phosphate-
induced rises of SC5b-9 levels is a reflection of complement activation rather than 
modulation of the terminal pathway only.  
The PEG moiety of liposomes, regardless of their molecular weight, plays no role in 
complement activation as demonstrated in experiments with endotoxin-free near 
monodisperse PEG1960 (polydispersity index = 1.03) and PEG400 (polydispersity index 
= 1.07). Neither PEGs (2.5 mg/ml, final concentration in serum) were able to raise serum 
levels of C4d, Bb, and SC5b-9 levels above the background (Fig. 2.3).  
 
2.3.4 The effect of surface mPEG-density and vesicle size 
Increasing the bilayer concentration of anionic Conj-A above 2.5 mol% elevated serum 
SC5b-9 levels, and the effect was more dramatic with vesicles bearing 10–15 mol% 
Conj-A (Table 2.1). Similar observations were made with DPPC vesicles containing the 
corresponding levels of DPPE-mPEG350. These experiments indicated the importance of 
surface charge density in complement activation. This is a surprising observation, since 
the high density of surface projected mPEG chains, which are believed to assume a 
mushroom-brush conformation (Tirosh et al., 1998; Chiu et al., 2001; Moghimi, 2006; 
Kenworthy et al., 1995), should sterically shield the liposome surface against protein 
adsorption.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. The effect of near monodisperse PEG1960 and PEG400 on complement 
activation. 
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Table 2.1. The effect of liposome size and bilayer composition on SC5b-9 generation 
in human serum 
 
 
 SC5b-9 (µg/ml) 
Liposome composition 
(mole ratio) 
85 nm liposomes 140 nm liposomes 260 nm liposomes 
DPPC 2.3 ± 0.4 2.5 ± 0.1 1.9 ± 0.4 
DPPC:Conj-A (99:1) 2.6 ± 0.5 not done not done 
DPPC:Conj-A (97.5:2.5) 3.8 ± 0.8
*
 not done not done 
DPPC:Conj-A (95:5) 6.3 ± 0.4
*
 7.6 ± 1.1
**
 10.1 ± 1.0
**
 
DPPC:Conj-A (90:10) 8.1 ± 0.9
**
 not done not done 
DPPC:Conj-A (85:15) 8.5 ± 0.6
**
 9.2 ± 0.6
**
 12.2 ± 0.9
**
 
DPPC: Conj-B (95:5) 2.5 ± 1.0 3.0 ± 0.8 3.4 ± 0.4 
DPPC:Conj-B (85:15) 3.1 ± 0.6 2.9 ± 0.1 2.9 ± 0.2 
 
 
The baseline SC5b-9 level (control/PBS) was 2.5 ± 0.5 µg/ml. Liposomes were incubated 
with serum of subject 1 for 30 min at 37 °C prior to SC5b-9 measurement. Significant 
differences with respect to control/PBS: 
*
p<0.05, 
**
p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Since the described liposomes can activate complement, the discrepancies in cell uptake 
studies may be rationalized by the steric hindrance of mPEG chains to binding of 
opsonized vesicles to CD11b. Hence, these results are in agreement with the reported 
prolonged circulation times of PEGylated vesicles (Moghimi et al., 2001). In contrast to 
anionic conjugates, increasing the bilayer concentration of nonionic mPEG-lipid (Conj-
B) in DPPC vesicles to 15 mol% failed to elevate serum SC5b-9 levels above the 
baseline, and the results were comparable to non-complement activating DPPC vesicles 
(Table 2.1). This again confirms a role for the anionic phosphate oxygen in activating 
complement. 
Vesicle size have been demonstrated to play a critical role in complement activation; 
smaller vesicles (sub 100 nm) are less effective complement activators than their larger 
counterparts for equivalent concentrations (Szebeni et al., 2000; Devine et al., 1994; 
Bradley et al., 1998). This reflects the importance of geometric factors and surface 
dynamics on the initial assembly of proteins involved in complement activation. In 
addition, surface curvature affects projected mPEG chain conformation; this in turn may 
exert some control over complement consumption and activation (Moghimi & Szebeni, 
2003; Gbadamosi et al., 2002). The results in Table 2.1 further confirm the non-
complement activating nature of larger-sized Conj-B bearing liposomes when tested with 
bilayer concentrations up to 15 mol%. However, increasing size causes more complement 
activation with vesicles containing Conj-A.  
 
 
 
 
  
2.3.4 Liposome-mediated complement activation in rats 
Next, this study examined complement activation in vivo. Although a correlation between 
in vitro-in vivo dose responses is difficult, complement activation occurs at the point of 
injection with low doses of activator (Szebeni et al., 1994). intravenous injection of 
liposomes containing 5 mol% of anionic phospholipid-mPEG conjugates (regardless of 
mPEG chain length) was associated with a significant reduction in serum total hemolytic 
activity on a time scale of minutes with a parallel rise of TXB2 (Fig. 2.4). TXB2 is an 
established and direct marker for TXA2 production (Szebeni et al., 1994). 
Anaphylatoxins arising from complement activation (C3a and C5a) induce TXA2 release 
from blood cells, thus demonstration of increased serum TXB2 levels provide further 
evidence for in vivo PEGylated liposome-mediated complement activation (Szebeni et 
al., 1994). On the contrary, neither in vivo TXB2 levels nor in vitro complement activity 
in serum (CH50 measurements) was affected with liposomes bearing nonionic lipid-
mPEG conjugate (Fig. 2.4), thus confirming a role for the negative charge of phosphate 
oxygen in complement activation. 
 
2.3.5 The involvement of both classical and alternative pathways 
Having established a critical role for anionic phospholipid-mPEG conjugates in 
liposome-mediated complement activation, this study next sought to investigate through 
which pathway(s) complement activation proceeds. Calcium is essential for operation of 
both classical and MBL pathways, whereas operation of the alternative pathway is fully 
maintained in EGTA-chelated (Mg
2+
 supplemented) serum (Szebeni et al., 1994 and 
1997).  
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Fig. 2.4. Plasma TXB2 levels in rats following bolus intravenous injection of 
liposomes (80 mg/Kg in 0.5 ml). Liposomes were composed of DPPC and 5 mol% of 
designated conjugates (size range 80-130 nm). With the exception of Conj-B, CH50 
values were significantly different from baseline. (P< 0.05).  
 
 
 
 
 
 
 
 
 
  
Studies in EGTA-chelated sera of the five individuals demonstrated significant but 
variable reduction (15–60%, depending on serum) in SC5b-9 levels following challenge 
with liposomes bearing anionic phospholipid-mPEG conjugates. This confirmed a direct 
role for the alternative pathway, rather than amplification of C3 convertase initially 
triggered through calcium-sensitive pathways. To address the role of calcium-sensitive 
pathways, this study also followed the liposome-induced changes in C4d levels in sera, 
and these were elevated by 1.8- to 3-fold above the background level as determined by 
ELISA, depending on serum source.  
To further elucidate the mechanism of complement activation by anionic phospholipids-
mPEG conjugates C1q-depleted serum was used, which enables clarification of the role 
of C1q-dependent classical pathway activation. The results in Fig. 2.5 show a significant 
reduction in SC5b-9 generation in C1q-depleted serum with liposomes bearing anionic 
phospholipid-mPEG conjugates, when compared to incubations with restored 
physiological levels of the deficient factor (C1q), thus confirming the involvement of 
C1q-dependent classical pathway. As a positive control, zymosan-mediated complement 
activation proceeded efficiently in C1q deficient serum and the process was unaffected 
following the addition of C1q, as zymosan activates complement via all three pathways. 
Notably, liposome-mediated elevation of SC5b-9 in C1q-depleted serum was 
significantly above the baseline level (Fig. 2.5). This was due to direct involvement of the 
alternative pathway, since SC5b-9 levels in EGTA-chelated (Mg2+ supplemented) C1q-
depleted serum remained unchanged. Furthermore, immunochemical depletion of factor 
B in C1q-depleted serum totally abolished SC5b-9 generation by both liposomes and 
zymosan (control experiment) providing further evidence for direct involvement of the 
alternative pathway. 
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Fig. 2.5. Liposome-mediated SC5b-9 generation in C1q-depleted human serum. 
DPPC liposomes were used and contained 10 mol% of designated conjugates in their 
bilayer (size range 80-130 nm). (*P< 0.05). 
 
 
 
 
 
 
 
  
 
This study did not investigate contribution of the MBL pathway, since MBL selectively 
recognizes glucans, lipophosphoglycans and glycoinositol phospholipids that contain 
mannose, glucose, fucose, or N-acetylglucosamine as their terminal hexose, and none of 
which were presented on the tested liposomes (Moghimi & Hunter, 2001; Gulati et al., 
2002). 
 
2.3.6 The role of phospholipid head-group—A hypothesis 
In contrast to PEGylated liposomes, anionic phospholipid-mPEG350 and -mPEG2000 
conjugates in micellar form were incapable of rising serum SC5b-9, C4d, Bb and C3a-
desarg levels above the respective baseline. Thermodynamically, micelle solution is at 
equilibrium; the concentration of monomers being equal to the critical micelle 
concentration. Hence, neither anionic phospholipid-mPEG monomers nor micelles are 
capable of activating the human complement system. However, lack of complement 
activation by these micelles may be due to their small hydrodynamic size, which was in 
the region of 25–32 nm as determined by photon correlation spectroscopy. On the 
contrary, related nonionic micelles (2.5–10 mg/ml) of similar sizes such as those 
assembled from polyoxyethene/poloxypropylene block copolymers (eg, poloxamer 407 
and poloxamine 908) activate complement in human serum (2- to 4-fold rise in serum Bb 
and SC5b-9 levels above the respective background). On the basis of these observations, 
a possible role for liposomal zwitterionic phospholipid head-groups as an additional (or 
prerequisite) factor contributing to complement activation can not be excluded. Recent 
studies have demonstrated that following incubation in serum, the surface of PEGylated 
liposomes becomes coated with apolipoproteins, antibodies and complement proteins 
  
(Szebeni et al., 2000; Price et al., 2001; Moghimi & Szebeni, 2003). It is therefore 
proposed that for binding to PEGylated liposomes, complement activating natural anti-
phospholipid antibodies (IgG and IgM) may require the presence of both DPPC head-
groups and the anionic moiety of phospholipid-mPEG in a spatial relationship that orients 
the antibody into a complement activating posture. Indeed, structural modelling studies 
have demonstrated that the Fab/Fc orientation of IgG might    be a key factor in 
controlling access of the C1q globular B module to the CH2 domain of human IgG1 
(Gaboriaud et al., 2003 & 2004). Likewise, the globular internal A and/or C modules of 
C1q show preferential binding to oligomeric IgM (Gaboriaud et al., 2004; Kishore et al., 
2003). It is also known that antibodies can activate the alternative pathway via their F(ab) 
portion (Moore et al., 1982; Fries et al., 1984), whose binding of C3b is also likely to 
depend on a two antigenic subsite-fixed orientation of IgG.  Thus, on the basis of this 
study’s observations, it could be further suggested that the steric arrangement imposed by 
the bulky methyl group in Conj-B either prevents simultaneous binding of anti-
phospholipid antibodies to the phosphate oxygen moiety of both phospholipid head-
groups and phospholipid-mPEG conjugates and/or interfere with spatial organization of 
surface-bound antibodies for correct recognition by all three modules of globular C1q 
domain.  
It is also appropriate to stress here that the presence or absence of additional epitopes for 
anti-phospholipid antibody binding, such as apolipoprotein-H, (Alving & Swartz 1991; 
Szebeni et al., 1996; McNiel et al., 1990) and direct binding of C1q (Bradley et al., 
1999a and b) to the anionic bilayer surface are further factors for consideration. As for 
the latter process, the top of the C1q head is predominantly basic and as a result C1q can 
function as a charge pattern recognition molecule. Indeed, the highly cationic region of 
  
C1q A chain, comprising residues 14–26, binds to cardiolipin-containing liposomes 
(Bradley et al., 1999a). Binding of C1q to phosphatidylglycerol-containing liposomes has 
also been demonstrated (Bradley et al., 1999b) where following binding C1q and 
phosphatidylglycerol colocalize into domains with characteristic radii of curvature higher 
than that of the surrounding bilayer, which eventually bud into small vesicles. 
Hydrophobic interactions and/or hydrogen bonding have also been suggested to 
participate in the binding of C1q to cardiolipin-containing liposomes (Bradley et al., 
1999b); hydrogen bonding is presumably mediated by the central 2´-hydroxyl moiety of 
the glycerol backbone of cardiolipin. With respect to these observations and the results in 
Fig. 2.5, a direct role for small numbers of C1q molecules in initiating complement 
activation by liposomes bearing anionic phospholipid-mPEG conjugates can not be 
excluded. Thus, in addition to electrostatic interactions between C1q and the anionic 
phosphate oxygen, the ether oxygen groups in the mobile mPEG moiety may play a role 
in accommodating C1q on the liposome surface via hydrogen bonding.  
 
2.4 Conclusion 
Methoxypoly(ethylene glycol), (mPEG),-grafted liposomes are known to exhibit 
prolonged circulation time in the blood, but their infusion into a substantial percentage of 
human subjects triggers immediate non-IgE-mediated hypersensitivity reactions. These 
reactions are strongly believed to arise from anaphylatoxin production through 
complement activation. Despite the general view that vesicle surface camouflaging with 
mPEG should dramatically suppress complement activation, here this study shows that 
bilayer enrichment of non-complement activating liposomes 
(dipalmitoylphosphatidylcholine, DPPC, vesicles) with phospholipid-mPEG conjugate 
  
induces complement activation resulting in vesicle recognition by macrophage 
complement receptors. The extent of vesicle uptake, however, is dependent on surface 
mPEG density. This study has delineated the likely structural features of phospholipid-
mPEG conjugate responsible for PEGylated liposome-induced complement activation in 
normal as well as C1q-deficient human sera, using DPPC vesicles bearing the classical as 
well as newly synthesized lipid-mPEG conjugates. With PEGylated DPPC vesicles, the 
net anionic charge on the phosphate moiety of phospholipid-mPEG conjugate played a 
key role in activation of both classical and alternative pathways of complement and 
anaphylatoxin production (reflected in significant rises in SC5b-9, C4d and C3a-desarg 
levels in normal human sera as well as SC5b-9 in EGTA-chelated/Mg
2+
 supplemented 
serum), since methylation of the phosphate oxygen of phospholipid-mPEG conjugate, 
and hence the removal of the negative charge, totally prevented complement activation. 
To further corroborate on the role of the negative charge in complement activation, 
vesicles bearing anionic phospholipid-mPEG conjugates, but not the methylated 
phospholipid-mPEG, were shown to significantly decrease serum hemolytic activity and 
increase plasma thromboxane B2 levels in rats. In contrast to liposomes, phospholipid-
mPEG micelles had no effect on complement activation, thus suggesting a possible role 
for vesicular zwitterionic phospholipid head-groups as an additional factor contributing to 
PEGylated liposome-mediated complement activation. These findings provide a rational 
conceptual basis for development of safer vesicles for site-specific drug delivery and 
controlled release at pathological sites.  
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Chapter three  
Complement Activation by PEGylated Single-Walled 
Carbon Nanotubes is Independent of the C1q-
Dependent Classical and the Alternative Pathways 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3.1 Introduction 
 
Carbon nanotubes have received considerable attention as promising materials for a 
wide range of experimental diagnostic and therapeutic applications following 
intravenous injection (Lacerda et al., 2006; Liu et al., 2007; Liu et al., 2008). 
However, the interaction between carbon nanotubes and the complement system, 
which is an important effector arm of both innate and acquired immunity (Lambris et 
al., 2008), has not received much attention. The complement system can be triggered 
by three separate pathways: the classical, the lectin and the alternative pathways 
(Lambris et al., 2008). Three consequences arise from complement activation 
(Lambris et al., 2008). These include priming of the activator surface by opsonic 
complement fragments (e.g., C3b, iC3b) for engulfment by phagocytes, generation of 
anaphylatoxins and chemoattractants (eg, C3a, C5a) and formation of the membrane 
attack complex (C5b-9) (Fig. 1.1).  To date, an isolated study with non-functionalized 
high pressure carbon monoxide single-walled carbon nanotubes (HIPco SWNTs) and 
double-walled carbon nanotubes (DWNTs) has revealed nanotube-mediated 
complement activation in human serum (Salvador-Morales, et al., 2006). Recently, 
Salvador-Morales et al., suggested that HIPco SWNTs and DWNTs activate 
complement through classical pathway which was mediated by surface adsorption of 
the C1q component of complement, DWNTs, on the other hand, activated 
complement through the alternative pathway (Salvador-Morales, et al., 2006).   
Nanotube stability in the blood can be enhanced by surface functionalization with 
poly(ethyleneglycol)5000-phospholipid (PEG5000-PL) conjugates (Liu et al., 2007). 
Such surface modification procedures also confer longevity to SWNTs in the systemic 
circulation (SWNTs reported half life is 12h); this is most likely arises from the steric 
hindrance of the projected long PEG chains to nanotube–macrophage interaction 
  
(Moghimi et al., 2001; Moghimi & Szebeni, 2003; Moghimi et al., 2006). Indeed, 
PEGylated SWNTs, through prolonged circulation times in the blood, can ultimately 
target elements of tumour vasculature following conjugation of targeting ligands to 
the distal end of the projected PEG chains (Liu et al., 2007). Recent studies with 
PEGylated liposomes such as Doxil
®
 (a clinically approved PEGylated liposome with 
encapsulated doxorubicin) as well as PEGylated polymeric nanoparticles have 
demonstrated that the steric hindrance of PEG may not necessarily prevent 
complement activation and fixation, and their administration into human subjects may 
initiate untoward reactions (Gbadamosi et al., 2002; Chanan-Khan et al., 2003; 
Moghimi & Szebeni, 2003; Szebeni, 2005).  For example, infusion of Doxil
®
 into a 
substantial percentage of human subjects has triggered immediate acute 
pseudoallergic reactions with symptoms of cardiopulmonary distress such as 
dyspnoea, tachypnoea, hypertension/hypotension and chest and back pain (Szebeni, 
2005). These reactions are strongly believed to arise through the generation of 
complement anaphylatoxins C3a and C5a, leading to the subsequent release of 
thromboxane A2 (TXA2) and other inflammatory mediators from immune cells 
(Szebeni, 2005; Chanan-Khan et al., 2003). Furthermore, the terminal half of the 
complement pathway generates multiprotein C5b-9 complexes (Lambris et al., 2008) 
and these have the capacity to elicit non-lytic stimulatory responses from vascular 
endothelial cells and, therefore, modulate endothelial regulation of haemostasis and 
inflammatory cell recruitment (Hamilton et al., 1993). In light of these observations, 
we sought to investigate the interaction of amino-PEG5000-
distearoylphosphatidylethanolamine (amino-PEG5000-DSPE) and 
methoxy(MeO)PEG5000-DSPE functionalized SWNTs with the complement system 
both in vitro and in vivo. 
  
 
 
3.2 Materials and methods 
3.2.1 Materials 
amino-poly(ethylenglycol)5000-(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) 
(amino-PEG5000-DSPE) and methoxy (MeO)-PEG5000-DSPE  were purchased from 
NOF Corporation, Japan. 
Dipalmitoylphosphatidylcholine (DPPC) and Fluka standard PEGs were obtained 
from Sigma-Aldrich (UK). 
Commercially available human C1q-depleted serum was obtained from Quidel 
(distributed by Technoclone, UK). 
MBL-C4 complex ELISA kit was purchased from HyCult Biotechnology, The 
Netherlands. 
Wielisa
®
-Total Complement Screen kit was obtained from Lund, Sweden. 
Sephacryl S-200-HR gel was obtained from Sigma-Aldrich, UK. 
Futhan, Mouse monoclonal antibodies to human C1s (IgG1, clone M81), MBL, L-
ficolin (clone GN5) and H-ficolin (clone 4H5) were from HyCult Biotechnology (The 
Netherlands). 
 
 
 
  
3.2.2 Methods 
3.2.2.1 Preparation of PEGylated SWNTs 
As-grown SWNTs were sonicated in the presence of either 1 mg/mL amino-
poly(ethyleneglycol)5000-(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) (amino-
PEG5000-DSPE) or methoxy (MeO)-PEG5000-DSPE for 1 h followed by centrifugation 
at 24,000 X g for 6 h to remove large bundles, aggregates and impurities (Lacerda et 
al., 2006). Excess PEG-phospholipid conjugates were removed by filtration through 
100-kDa Millipore filters.  
3.2.2.2 PEGylate liposomes 
Liposomes were composed of dipalmitoylphosphatidylcholine (DPPC) and 
MeOPEG2000-DPPC (mole ratio 9.5:0.5) and prepared by hydrating the dried lipid 
film with 10 mM phosphate-buffered saline (pH 7.2) and then extruded through 
polycarbonate Nuclopore filters with pore diameters of 200 nm using a high-pressure 
extruder. The prepared liposomes were 118 ± 12 nm in size (polydispersity index = 
0.07), determined by laser light scattering (Liu et al., 2008). 
 
3.2.2.3 Preparation of human serum 
Blood was drawn from healthy male volunteers according to approved local protocols. 
Blood was allowed to clot at room temperature and serum was prepared, aliquoted 
and stored at -80°C. Serum samples were thawed and kept at 4°C before incubation 
with test reagents. Commercially available human C1q-depleted serum was obtained 
from Quidel. 
  
 3.2.2.4  Assays of in vitro complement activation 
To measure complement activation in vitro, this study determined SWNT-induced 
rise of serum complement activation product SC5b-9, Bb and C4d, using respective 
Quidel’s ELISA kits according to the manufacturer’s protocols as described 
previously (Liu et al., 2008; Lambris et al., 2008). As a result of substantial biological 
variation in serum levels of complement proteins and the large number of positive and 
negative feedback interactions, this study monitored generation of complement 
activation products in sera of 4 healthy individuals separately (Liu et al., 2008). The 
concentration of mannan binding lectin (MBL) in both healthy and C1q-depleted sera 
was determined by using the MBL-C4 complex ELISA kit. Only sera with 
physiological concentrations of MBL, in the range of 3000–5000 ng/mL, were 
selected for subsequent complement activation assays. The functional activity of 
classical, lectin and the alternative pathways of complement were confirmed in all 
sera with Wielisa
®
-Total Complement Screen kit (Lund, Sweden).  
For measurement of complement activation, the reaction was started by adding the 
required quantity of SWNTs to undiluted serum (SWNT to-serum volume ratio 1:4) in 
Eppendorf tubes (in triplicate) in a shaking water bath at 37°C for 30 min, unless 
stated otherwise. Reactions were terminated by addition of “sample diluent” provided 
with assay kit. SWNT-induced rises of serum SC5b-9, Bb and C4d were then 
measured following nanotube removal (to minimize interference in ELISA tests) by 
carefully layering 200 µL of Sephacryl S-200-HR gel and subsequent centrifugation. 
The extent of nanotube-trapping in the gel was followed by measuring the absorbance 
of the supernatant at 808 nm (e.g., ~70–75% of amino-PEG5000-DSPE coated 
nanotubes were trapped by these procedures). Subsequently, appropriate controls 
were also made by adding sufficient quantities of SWNTs to saline for background 
  
correction in ELISA experiments. The gel-trapping procedures had no effect in 
removing fluid phase complement activation products (as will be shown in results). 
Control serum incubations contained saline (the same volume as nanotubes and other 
additions) for assessing background levels of SC5b-9, Bb and C4d. Zymosan was 
used as a positive control for complement activation (Liu et al., 2008; Lambris et al., 
2008). To monitor the possible binding of complement activation products to the 
nanotube surface, SWNTs were incubated with standard samples of activation 
products. The level of the standard activation products in the supernatant was then 
measured by the respective ELISA test and compared with control incubations in the 
absence of nanotubes. In some experiments, SWNT-induced complement activation 
was monitored following pretreatment of serum with EDTA (20 mM final 
concentration), Futhan (150 µg/mL), and monoclonal antibodies (against C1s, MBL, 
H- and L-ficolins, or an irrelevant antibody). The anti-C1s monoclonal antibody, but 
not an irrelevant murine IgG antibody, blocked activation of the classical pathway in 
human serum as confirmed by complement activation experiments (C4d 
measurements) in the presence of cholesterol-rich liposomes (these liposomes activate 
complement through the classical pathway) (Moghimi et al., 2001; Moghimi & 
Szebeni, 2003). 
For quantification of complement activation products, standard curves were 
constructed using the assigned concentration of each respective standard supplied by 
the manufacturer and validated. The slope, intercept and correlation coefficient of the 
derived best-fit line for Sc5b-9, Bb and C4d standard curves were within the 
manufacturer’s specified range. 
The efficacy of SWNT treatments was established by comparison with baseline levels 
using paired t test; correlations between two variables were analysed by linear 
  
regression, and differences between groups (when necessary) were examined using 
ANOVA followed by multiple comparisons with Student-Newmann-keuls test. 
Similar patterns were observed in all tested sera; the result of a typical experiment is 
presented. 
 
3.2.2.5 Determination of thromboxane B2 (TXB2) level in rat blood 
Prior to intravenous injection of SWNT, PEG-Phospholipids and liposome, 1.0 mL 
blood was taken from the tail vein of male Wistar rats (250–280 g) for plasma 
preparation to obtain the required baseline parameters. For plasma preparations, blood 
was collected in EDTA/0.25 mM indomethacin-containing tubes to prevent 
prostaglandin metabolism. Bolus intravenous injections (SWNT, 1.2 mg/kg, PEG-PL 
conjugates, up to 10 mg/kg; PEGylated liposomes, 80 mg/kg) were made through the 
opposite tail vein. Further blood samples were taken at 6 and 60 min post-injection to 
obtain plasma. Plasma TXB2 levels were determined in triplicate samples (Liu et al., 
2008; Moghimi & Szebeni, 2003) by following the procedures supplied with the 
ELISA kit. 
 
3.3 Results and Discussion 
The diameters and lengths of functionalized nanotubes were 1–5 nm and 50–300 nm, 
respectively, as determined by AFM (Fig. 3.1). The binding of PEG-PL conjugates 
represents a minimum available surface area, where the projected PEG chains are 
expected to assume a ‘brush-like’ or laterally compressed elongated random coil 
configuration, which is a necessary prerequisite for minimizing and/or combating 
  
protein adsorption (Moghimi & Szebeni, 2003; Gbadamosi et al., 2002). The 
prolonged stability of PEGylated SWNTs in both buffer and fresh serum was 
confirmed earlier (Liu et al., 2007). 
During complement activation, C5b-9 complexes formed in the absence of a target 
membrane bind to a naturally occurring regulatory serum protein, the S protein; the 
generated SC5b-9 complex is the soluble, non-lytic form of the terminal attack 
complex (Lambris et al., 2008). Therefore, this study monitored nanotube-mediated 
complement activation in sera of healthy subjects by measuring SC5b-9 generation by 
enzyme-linked immunosorbent assay (ELISA) (Chanan-Khan et al., 2003; Szebeni, 
2005). PEGylated nanotubes caused complement activation, irrespective of the 
terminal end moiety of the projected PEG chains, as evident with significant rises of 
serum SC5b-9 levels over baseline at a final nanotube concentration of 40 µg/mL 
(Figure 3.2a), with a trend of reaching maximal efficacy at 60–80 µg/mL. Nanotube-
mediated SC5b-9 generation also proceeded on a time scale of minutes and reached 
plateau at around 10 min. In contrast to PEGylated SWNTs, PEG-PL conjugates, even 
at concentrations as high as 2 mg/mL (twice above the PEG-PL conjugates initially 
used for SWNT stabilization), did not elevate serum SC5b-9 levels; this was also in 
accordance with the previous studies (Moghimi et al., 2006).  
 
 
 
 
 
 
 
  
(a) (b)
 Fig. 3.1 An atomic force microscope image of amino-PEG5000-DSPE 
functionalized SWNTs over a SiO2 substrate (a) and a photograph of MeO-
PEG5000-DSPE stabilized SWNT suspension (b). Similar AFM images were also 
obtained with MeO-PEG5000-DSPE stabilized SWNTs. Scale bar = 250 nm. Photon 
correlation spectroscopy further revealed a mean particle size (equivalent spherical 
size) of 259 nm and a modal particle size of 214 nm for amino-PEG5000-DSPE 
functionalized SWNTs. The corresponding values for MeO-PEG5000-DSPE 
functionalized SWNTs were 175 nm and 117 nm, respectively. 
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Fig. 3.2 PEGylated SWNT-mediated complement activation in human serum. 
SC5b-9, Bb and C4d levels in human serum. In (a) SC5b-9 levels reached maximum 
at a final nanotube concentration of 60 µg/mL of serum (not shown); the results are 
similar to those at 80 µg/mL. Zymosan was used as a positive control. No 
complement activation was achieved by the coating materials in the absence of 
nanotubes, even at concentrations at high as 2 mg/mL in serum. Significant difference 
with respect to control (saline): *p<0.05, **p<0.01. 
  
This study next sought to investigate through which pathway(s) nanotube-mediated 
complement activation proceeds, starting with the alternative pathway. The alternative 
pathway is stimulated by the spontaneous cleavage of thioester bond in C3 or when 
the internal thioester bond in the α-chain of nascent C3b undergoes nucleophilic 
attack in the presence of a foreign surface structure rich in nucleophilic groups 
(particularly hydroxyl- and amino-rich surfaces) (Szebeni et al., 1998; Lambris et al., 
2008; Toda et al., 2008). These structural modifications in C3 firstly allow the 
binding of complement Factor B, and secondly promote its cleavage by factor D thus 
initiating the formation of the C3 convertase C3bBb. Subsequently, through 
spontaneous decay and/or mediation of complement factor H, the 60 kD Bb fragment 
becomes dissociated from the C3 convertase (Lambris et al., 2008). This split-product 
(Bb) is indeed a specific marker of complement activation through the alternative 
pathway and can be measured by ELISA in the fluid phase (Szebeni et al., 1998). 
There was no effect of PEGylated SWNTs on serum Bb levels even at concentrations 
as high as 80 µg nanotube/mL (Fig. 3.2b); this was rather surprising since the 
projected surfaces are rich in nucleophilic groups (Toda et al., 2008). Control 
experiments, with standard Bb samples, further confirmed that Bb has no affinity for 
the nanotube surface. The lack of factor B cleavage also exclude a role for direct C3 
adsorption to SWNTs with subsequent formation of the C3Bb convertase through 
altered C3 conformational changes that resembles C3b; such mode of activation was 
recently reported for the polystyrene surface (Andersson et al., 2002). Nevertheless, 
these results are in-line with the recent suggestion of Salvador-Morales et al. (2006), 
where non-functionalized HIPco SWNTs also failed to activate human complement 
through the alternative pathway.  
  
Classical pathway activation is triggered when the hexameric C1q subcomponent of 
C1 binds to an activator. This induces a conformational change within the C1 
complex resulting in conversion of the zymogen C1s subcomponent into an active 
proteloytic enzyme that subsequently activates the C1s subcomponent (Lambris et al., 
2008). Activation of the lectin pathway proceeds following the binding of mannose 
binding lectin (MBL) or ficolins to an activator. Both MBL and ficolins are 
complexed with MBL-associated serine proteases (MASPs)-1,  -2 , -3 and the 
sMAp19 protein in their proenzyme forms; it is the binding of MBL and ficolin to an 
activator that induces a conformational change in MASPs and convert them into 
active proteloytic enzymes (Vorup-Jensen et al., 2000; Matsushita et al., 2000; Fujita, 
2002). The activated form of the serine protease C1s of the classical pathway and the 
MASP-2 of the lectin pathway, both cleave the C4 protein; this in turn activates C2 
thus leading to subsequent generation of the classical/lectin pathway C3 convertase, 
C4b2a (Lambris et al., 2008, Vorup-Jensen et al., 2000; Fujita, 2002). One of the final 
fluid phase degradation products of C4 cleavage is the C4d fragment, and this is an 
established marker of complement activation initially triggered through both classical 
and lectin pathways (Moghimi et al., 2006; Szebeni et al., 1997). In this study, 
SWNTs elevated fluid phase C4d levels in all tested human sera by 2–3 fold above 
the background level as determined by ELISA (Fig. 3.2c), thus indicating the role of 
these two pathways in nanotube-mediated complement activation. In agreement with 
SC5b-9 measurements, PEG-PL conjugates were shown not to elevate serum C4d 
levels (Moghimi et al., 2006). Next, a C2-depleted human serum was used to confirm 
that the observed SWNT-mediated elevation of SC5b-9 (in Fig. 3.2a) was dependent 
on the generation of C4b2a convertases, as these convertases trigger downstream 
  
reactions. Indeed, in C2-depleted serum SWNTs failed to dramatically elevate SC5b-9 
levels (872 ± 54 ng/mL serum) above the background (811 ± 28 ng/mL serum). 
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Fig. 3.3 PEGylated SWNT-mediated rises of the fluid phase C4d in C1q-depleted 
human serum. In (a) the final nanotube concentration in serum was 40 µg/mL. 
Zymosan was used a positive control for monitoring activation of the lectin pathway. 
Significant difference is compared with the respective control (saline or EDTA): 
*p<0.05, **p<0.01. 
 
 
 
  
To further distinguish between the calcium-sensitive C1q-dependent classical 
pathway and the lectin pathway mode of activation, a C1q-depleted human serum was 
used (with physiological MBL and C3 levels). Remarkably, nanotubes induced 
significant elevation of C4d levels in the C1q-depleted serum both in the absence and 
the presence of EDTA (Fig. 3.3a); this is in contrast to non-functionalized carbon 
nanotubes where complement activation was reported to occur directly via C1q 
binding (Salvador-Morales et al., 2006). To further eliminate a direct role for the 
serine protease C1s in PEGylated SWNT-mediated complement activation, a C1q-
depleted serum was pretreated with a monoclonal antibody against C1s (the antibody 
recognizes the binding site of C1s for C4 and reacts with both active and inactive 
C1s). Again, nanotubes significantly elevated C4d and SC5b-9 levels in serum above 
the respective baselines (incubations in the presence of an irrelevant antibody), thus 
eliminating the role of the classical pathway in SWNT-mediated complement 
activation. PEGylated SWNTs, therefore, most likely trigger complement activation 
through the lectin pathway (Fig. 3.5); further indication for the involvement of lectin 
pathway in nanotube-mediated complement activation was derived from experiments 
with Futhan (Fig. 3.3b), a serine protease inhibitor with broad specificity, and which 
is known to prevent complement activation through all three pathways (Pfeifer et al., 
1999). Elevation of nanotube-mediated rises of serum SC5b-9 was also halted in the 
presence of Futhan in the C1q-depleted serum and was comparable to the background 
level (not shown). Throughout these experiments zymosan was used as a positive 
control; zymosan-mediated C4d elevation proceeded in C1q-depleted serum (an 
established mode of activation through the lectin pathway) but was partly suppressed 
in the presence of EDTA (a calcium-binding-mediated role for MBL) (Moghimi et al., 
2006).  
  
To establish whether PEGylated SWNTs are also capable of inducing complement 
activation in vivo, this study monitored plasma thromboxane B2 (TXB2) levels 
following intravenous nanotube injection into rats. TXB2 is a direct marker for 
TXA2. When complement is activated in vivo, then generated anaphylatoxins C3a 
and C5a usually induce TXA2 release from blood cells, but due to its short half-life 
(~30 seconds) TXA2 is hydrolyzed rapidly to TXB2. Thus, TXA2 formation can be 
monitored by quantifying TXB2 and demonstration of increased serum TXB2 levels 
provides evidence for in vivo SWNT-mediated complement activation (Moghimi et 
al., 2006; Szebeni et al., 1997). Erratic responses were observed in rats; while in some 
animals nanotube administration (1.2 mg/kg) was associated with a significant rise in 
plasma TXB2 level on a timescale of minutes with return to background levels at 1 h 
(a feature consistent with complement activation), other rats showed no response (Fig. 
3.4). In contrast to nanotubes, intravenous administration of PEG-PL conjugates (1.2 
mg/kg) did not alter plasma TXB2 levels, which was also in agreement with previous 
studies (Moghimi et al., 2006). As a positive control, PEGylated liposome 
administration induced rises in plasma TXB2 levels in all tested rats. The lack of 
response to SWNT injection in some rats could be due to generation of insufficient 
quantities of anaphylatoxins C3a and C5a necessary for initiating immune cell 
degranulation either directly or through the release of a secondary co-stimulus, such 
as those arising from the kallikrein-kinin system (Szebeni, 2005; Hamad & Moghimi, 
2008). It is also plausible that, in contrast to human serum, SWNT-mediated 
complement activation could proceed through other pathways in the rat model. 
However, if nanotube-mediated complement activation in rats is through the lectin 
pathway, then the observed variations may arise as a result of different levels of 
plasma MBL- or ficolin-/MASPs and/or MASP activity among individual animals. 
  
Liposome-mediated complement activation, however, occurs through both antibody-
mediated C1q-dependent and alternative pathways in the described model, which 
presumably raises sufficient quantities of anaphylatoxins necessary for subsequent 
immune cell degranulation (Moghimi et al., 2006; Szebeni et al., 1997).  
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Fig. 3.4 Plasma TXB2 levels in rats following bolus intravenous injection of 
PEGylated SWNTs, PEG-PL conjugates and PEGylated liposomes. Data from 
each individual animal is shown. For MeOPEG-PL, 4 rats were also used and no 
responses were observed; only two representative examples are shown. Even at higher 
concentrations of MeOPEG-PL, (tested up to 10 mg/kg), TXB2 levels were 
comparable to the background (not shown). Significant difference is compared with 
the 0 min (baseline, TXB2 level in plasma prior to nanotube, MeOPEG-PL and 
liposome injection): *p<0.05, **p<0.01. 
 
  
 
Fig. 3.5 Proposed schematic representation of SWNT-mediated complement 
activation via the lectin pathway. Plasma MBL and/or ficolin presumably bind in a 
simultaneous manner to some structural determinants of both the projected PEG 
chains and the nanotube surface. However, MBL and ficolins express specificity for 
sugars with N-acetylated groups, but these structures are absent on the surface of the 
native PEGylated  SWNTs. It is most likely that the recognition domain for MBL and 
ficolin binding is provided via some other adsorbed serum components, such as 
apolipoproteins. Hydrophobic interactions may also play some role in MBL/ficolin 
binding to PEG chains/nanotube surface as well as electrostatic interactions between 
MBL/ficolin and the anionic phosphate oxygen moiety of the PEG-PL conjugate. 
Nevertheless, this binding activates MASP-2, a serine protease that is initially 
associated in a proenzyme form with both MBL and ficolin. Activated MASP-2 
cleave complement component C4, and this in turn cleave the next complement 
protein (C2) to form the C4b2a convertase, which subsequently triggers downstream 
reactions (C3 conversion, anaphylatoxin generation, and formation of the membrane 
attack complex C5b-9).   
 
 
 
  
3.4 Conclusion 
Aminopoly(ethyleneglycol)5000-distearoylphosphatidylethanolamine  (aminoPEG5000-
DSPE) and methoxyPEG5000-DSPE coated as-grown HIPco single-walled carbon 
nanotubes activate complement in undiluted human serum. Complement activation 
was independent of both the classical (C1q-dependent) and the alternative pathways, 
but the data from C1q-depleted sera strongly suggest a likely role for the involvement 
of the lectin pathway. Moreover, intravenous injection of nanotubes in some rats was 
associated with a significant rise in plasma thromboxane B2 levels, indicative of in 
vivo nanotube-mediated complement activation.  
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Chapter four: 
 
Poly(ethylene glycol)s trigger complement activation in 
human serum through alternative and lectin pathways: a 
plausible cause for anaphylaxis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4.1 Introduction 
Poly(ethylene glycol) (PEG) is a linear polyether diol. This nonionic surfactant, which 
is commonly used in a wide range of human and veterinary pharmaceutical agents, 
has so far been perceived to be immunologically inert and safe, and is eliminated from 
the body intact by kidneys (for PEGs > 20000 gmol
-1
) following intravenous injection 
(Yamaoka et al., 1994; Harris & Chess, 2003). However, manufacturers data sheet on 
some high PEG content intravenous medicines (eg, as in veterinary settings) warns 
about unexplained acute adverse reactions such as ataxia, restlessness and trembling, 
respiratory abnormalities, frothing at the mouth, collapse and even death in cattle, 
sheep and swine receiving such formulations (Bio-Mycin
®
 200 Data Sheet, 2008). 
Interestingly, adverse non-IgE-mediated hypersensitivity reactions, which are also 
associated with cardiac anaphylaxis and rapid haemodynamic collapse, are known to 
occur in some humans and animals who have received intravenous formulations 
containing macromolecular nonionic surfactants that are structurally similar to PEG. 
Examples include polyethylene oxide-polypropylene oxide based block copolymers, 
such as poloxamer 188 (Tremper et al., 1984; Police et al., 1985; Kent et al., 1990).  
Block copolymers like poloxamer 188 can trigger complement activation both at sub-
micellar concentrations as well as in micellar forms (Moghimi et al., 2004), and the 
observed adverse responses following administration of poloxamer-based medicines 
are strongly believed to be secondary to complement activation through the 
generation of anaphylatoxins C3a and C5a, leading to the subsequent release of 
thromboxane A2 and other inflammatory mediators from immune cells (Moghimi et 
al., 2004; Vercellotti  et al., 1982; Ingram et al., 1993; Szebeni, 2005). Complement 
activation further generates the multiprotein terminal complex C5b-9, which has the 
capacity to elicit non-lytic stimulatory responses from vascular endothelial cells and, 
  
therefore, modulate endothelial regulation of haemostasis and inflammatory cell 
recruitment (Hattori et al., 2004).  
In light of these observations, it is imperative to examine whether PEG can trigger 
complement activation, although it has long been considered to be a safe and a 
“biocompatible” macromolecule. Such studies are also important particularly with the 
notion that PEG has recently been identified as a therapeutic agent per se in a variety 
of experimental therapeutics and veterinary settings (Hattori et al., 2004; Koob & 
Borgens, 2006). A remarkable example is the ability of intravenously injected 
PEG3500, particularly at high doses (600 mg/kg), to repair severe acute, naturally 
occurring paraplegia in dogs (Hansen type 1 lessions) (Hattori et al., 2004). PEG is 
believed to target the spinal cord contusion and “anatomically” seal the membranes of 
damaged axons through membrane fusion and restore excitability. Indeed, earlier, 
direct application of PEG to exposed contusion injuries in guinea pigs was shown to 
rapidly restore variable levels of nerve impulsed conduction through the lesion, as 
documented by a rapid recovery of both somatosensory evoked potential conduction 
and cutaneous trunchi muscle reflex (Borgens & Shi, 2000). Also, a recent study has 
further demonstrated that following traumatic axonal brain injury in rats, 
intravenously injected PEG can enter the brain parenchyma and repair cell membrane 
damage in corpus callosum and eliminate β-amyloid precursor protein accumulation 
in region of injury (Koob & Borgens, 2006). 
For the first time, this study will examine whether that near-monodisperse endotoxin-
free PEGs, at concentrations relevant to the above mentioned scenarios, can trigger 
complement activation in human sera. Depending on PEG concentration and Mw, and 
through which pathway/pathways this activation might proceed. 
 
  
4.2 Materials and methods 
4.2.1 Materials 
 Fluka standard PEGs were obtained from Sigma-Aldrich (UK). The weight average 
molecular weight (Mw) and the number average molecular weight (Mn) of PEG 
samples are presented in Table 4.1.  
The following materials were bought from Sigma-Aldrich-UK: Analar grade 
ethylendiaminetetraacetic acid disodium salt dehydrate (EDTA) 99%, 1,2-
dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phospho-rac-
(1-glycerol), cholesterol, zymosan, N-acetylglucosamine, D-galactose, D-mannose, 
pyridine, acetic anhydride, hydrochloric acid, ethyl acetate, copper sulfate, aqueous 
sodium hydrogen carbonate, sodium chloride and sodium sulfate. All solvents used in 
this research were 99% pure grades and used as received. 
Complement activation product SC5b-9, C3a-desArg, Bb and C4d ELISA kits, 
commercially available human C1q-depleted serum and C2-depleted serum, and A 
commercially available factor H were obtained from Quidel (distributed by 
Technoclone, UK). 
MBL-C4 complex ELISA kit and horseradish peroxidase-conjugated goat anti-mouse 
antibody were obtained from HyCult Biotechnology, The Netherlands. 
Wielisa
®
-Total Complement Screen kit was purchased from Lund, Sweden. 
4.2.2 Methods 
4.2.2.1 PEG diacetylation 
  
PEG4240 (100mg) in pyridine (40mL) and acetic anhydride (16mL) was stirred at room 
temperature overnight. The mixture was poured into dilute hydrochloric acid and the 
product extracted with ethyl acetate. The combined extracts were washed with copper 
sulfate solution, aqueous sodium hydrogen carbonate, water, saturated sodium 
chloride solution and dried over sodium sulfate. The solvent was removed in vacuo to 
afford diacetoxyPEG as a gum. Acetylation of the PEG4240 was confirmed by both 
1
H 
and 
13
C NMR spectroscopy [(CDCl3;360 MHz)  
1
H NMR 2.08 ppm (-COCH3) 3.64 
ppm (-CH2-); 
13
C NMR 19.81 ppm (-COCH3) 70.55 ppm (-CH2-) 169.89 ppm (-
COCH3)]. The 
1
H NMR of the starting material contained a signal at 3.64 ppm 
consistent with CH2 in the polymer backbone. In addition to this resonance the 
product contained a new peak at 2.08 ppm from the terminal methyl group of the 
acetate. Further structural support for the diacetylation was found in the 
13
C NMR 
spectrum of the product with new methyl (19.81 ppm) and quaternary carbon (169.89 
ppm) resonances present for the acetate group, but was devoid of the CH2OH signal in 
the starting material thus confirming acetylation had taken place. 
 
4.2.2.2 Liposome preparation 
 Unilamelar vesicles of 204 ± 39 nm (polydispersity index = 0.065),  and composed of 
1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phospho-
rac-(1-glycerol) and cholesterol in a mole ratio of 50:5:45 were prepared by hydrating 
the dried lipid film with 10 mM phosphate-buffered saline (pH 7.2) and subsequent 
extrusion through polycarbonate Nuclopore filters with pore diameters of 200 nm 
using a high-pressure extruder (Moghimi et al., 2006). Liposome size was determined 
by laser light scattering using Malvern Zetasizer 300 (Malvern Instruments, Malvern, 
UK) at 25 
0
C (Moghimi et al., 2006). 
  
4.2.2.3 Preparation of human serum 
Blood was drawn from healthy male volunteers according to approved local protocols. 
Blood was allowed to clot at room temperature and serum was prepared, aliquoted 
and stored at -80°C. Serum samples were thawed and kept at 4°C before incubation 
with test reagents. Commercially available human C1q-depleted serum and C2-
depleted serum were used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 4.1. PEG characteristics 
Designation Mw (gmol
-1
) Mn (gmol
-1
) Polydispersity (OCH2CH2)n 
PEG1960 1960 1900 1.032 n ~ 44 
PEG4240 4240 4120 1.029 n ~ 96 
PEG8350 8350 8100 1.031 n ~ 189 
PEG11600 11600 10800 1.074 n ~ 263 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4.2.2.4 Assays of in vitro complement activation  
To measure complement activation in vitro, this study determined PEG-induced rise 
of serum complement activation product SC5b-9, C3a-desArg, Bb and C4d, using 
respective Quidel’s ELISA kits according to the manufacturer’s protocols as 
described previously (Moghimi et al., 2004 and 2006). As a result of substantial 
biological variation in serum levels of complement proteins and the large number of 
positive and negative feedback interactions (Moghimi et al., 2006), this experiment 
monitored generation of complement activation products in sera of 5 healthy 
individuals separately. The concentration of mannan binding lectin (MBL) in healthy 
and selected complement protein-depleted sera was determined by using the MBL-C4 
complex ELISA kit. Only sera with physiological concentrations of MBL, in the 
range of 3000–5000 ng/mL, were selected for subsequent complement activation 
assays. The complement haemolytic activity of C1q-depleted serum and C2-depleted 
serum was restorable following the addition of C1q (180 µg/mL) and C2 (650 
µg/mL), respectively (Szebeni et al., 1994). The functional activity of classical, lectin 
and the alternative pathways of complement were confirmed in all sera with Wielisa
®
-
Total Complement Screen kit.  
For measurement of complement activation, the reaction was started by adding the 
required quantity of PEG solutions (in sterile physiological saline) or liposomes to 
undiluted serum (typically, 10 µl of PEG solution or liposomes were added to 40 µl of 
serum (in a 1:4 ratio)) in Eppendorf tubes (in triplicate) in a shaking water bath at 
37°C for a set period of 30 min. when stated and prior to PEG or liposomes addition, 
other components were added to serum to assess the role of individual pathways. 
Reactions were terminated by addition of “sample diluent” provided with assay kit. 
Control serum incubations contained saline (the same volume as PEGs or liposomes) 
  
for assessing background levels of complement activation products. Zymosan (5 
mg/mL) was used as a positive control for complement activation. The level of the 
complement activation products was then measured by the respective ELISA kits and 
compared with control incubations in the absence of PEG. In some experiments, PEG-
induced complement activation was monitored following pretreatment of serum with 
EGTA/Mg
2+
 (10 mM/2.5 mM), Futhan (150 µg/mL), N-acetylglucosamine (25 mM), 
D-galactose (25 mM) and D-mannose (25 mM). Control serum incubations contained 
the same quantity of the added compounds and PEG was replaced with the same 
volume of saline. 
For quantification of complement activation products, standard curves were 
constructed using the assigned concentration of each respective standard supplied by 
the manufacturer and validated. The slope, intercept and correlation coefficient of the 
derived best-fit line for SC5b-9, C3a-desArg, Bb and C4d standard curves were 
within the manufacturer’s specified range. The efficacy of PEG treatments was 
established by comparison with baseline levels using paired t test; correlations 
between two variables were analyzed by linear regression, and differences between 
groups (when necessary) were examined using ANOVA followed by multiple 
comparisons with Student-Newmann-keuls test. Similar patterns were observed in all 
tested sera; the result of a typical experiment is presented. 
4.2.2.5 SDS-PAGE and Western blot analyses 
Serum was treated with PEG4240 (5mM and 10 mM final concentration) or PEG11600 
(1.5 mM final concentration) for 5 min at room temperature. Aggregated proteins 
were precipitated by centrifugation (16000 x g, 20 min) and re-suspended in 
physiological saline. Proteins were then subjected to SDS-PAGE using 10–12% gels, 
  
immunoblotted with a murine monoclonal antibody against factor H (1:2000 v/v;) and 
bound factor H was detected using horseradish peroxidase-conjugated goat anti-
mouse antibody (1:2000). A commercially available factor H was used as a positive 
control. 
 
4.3 Results and discussion 
4.3.1 Activation of the whole complement pathway 
Activation of the terminal half of the complement pathway culminates in the 
formation of the C5b-9 complex, which in the absence of a target membrane binds to 
vitronectin (S protein) (Lambris et al., 2008). Therefore, PEG-mediated complement 
activation in human serum was first monitored by measuring the generation of the 
stable, soluble, non-lytic fluid-phase SC5b-9 complex, which is a sensitive measure of 
the activation of the whole complement cascade (Moghimi et al., 2004 and 2006). The 
results in Fig. 4.1 demonstrate that PEGs of varying Mws can activate complement in a 
concentration-dependent manner, but on molar basis high Mw PEG species are more 
effective in activating complement than their low Mw counterparts. The results (Fig. 
4.1e) also show a good correlation between SC5b-9 rises and PEG-mediated 
anaphylatoxin (C3a-desArg) generation, providing additional evidence that PEG-
induced rises of SC5b-9 levels in serum is a reflection of complement activation 
rather than modulation of the terminal pathway only.  
 
 
 
  
 
 
 
 
Fig. 4.1a. Complement activation as a function of PEG1960 concentration: 
PEG1960-mediated rises of SC5b-9 over background. The background SC5b-9 level 
in this particular serum (saline treated) was 873 ± 46 ng/mL. Zymosan (5 mg/mL) 
was used as a positive control and raised serum SC5b-9 levels by 3.32 fold. Similar 
patterns in SC5b-9 elevations were obtained in 4 other tested human sera. Significant 
difference is expressed with respect to the background (saline-treated serum): 
*p<0.05. 
 
 
 
 
 
 
  
 
 
 
 
Fig. 4.1b. Complement activation as a function of PEG4240 concentration: 
PEG4240-mediated rises of SC5b-9 over background. The background SC5b-9 level 
in this particular serum (saline treated) was 873 ± 46 ng/mL. Zymosan (5 mg/mL) 
was used as a positive control and raised serum SC5b-9 levels by 3.32 fold. Similar 
patterns in SC5b-9 elevations were obtained in 4 other tested human sera. Significant 
difference is expressed with respect to the background (saline-treated serum): 
*p<0.05. 
 
 
 
 
 
 
  
 
 
Fig. 4.1c. Complement activation as a function of PEG8350 concentration: 
PEG8350-mediated rises of SC5b-9 over background. The background SC5b-9 level 
in this particular serum (saline treated) was 873 ± 46 ng/mL. Zymosan (5 mg/mL) 
was used as a positive control and raised serum SC5b-9 levels by 3.32 fold. Similar 
patterns in SC5b-9 elevations were obtained in 4 other tested human sera. Significant 
difference is expressed with respect to the background (saline-treated serum): 
*p<0.05. 
 
 
 
 
 
 
  
 
 
 
Fig. 4.1d. Complement activation as a function of PEG11600 concentration: 
PEG11600-mediated rises of SC5b-9 over background. The background SC5b-9 
level in this particular serum (saline treated) was 873 ± 46 ng/mL. Zymosan (5 
mg/mL) was used as a positive control and raised serum SC5b-9 levels by 3.32 fold. 
Similar patterns in SC5b-9 elevations were obtained in 4 other tested human sera. 
Significant difference is expressed with respect to the background (saline-treated 
serum): *p<0.05. 
 
 
 
 
 
  
 
Fig. 4.1e. The influence of different molecular weights of PEG on anaphylatoxin 
C3a-desArg. All treatments elevated serum C3a-desArg levels significantly above 
baseline (p<0.05 in all cases). 
 
 
 
 
 
 
 
 
 
 
 
 
  
4.3.2 Alternative pathway mode of activation 
Biophysical evidence suggests that in an aqueous environment, PEG chains, as a 
result of forming hydrogen bonds with water molecules, assume helical conformation 
(Kozielski, 2006; Tasaki, 1996; Crupi et al., 1996). Statistically, more regions of 
“temporary ordering” or “structured water” are attainable with longer PEG chains 
compared with their shorter counterparts, and this may partly explain why higher Mw 
PEG species are more effective in triggering complement activating at far lower molar 
concentrations than low Mw PEGs. Here, complement activation most likely proceeds 
through the alternative pathway, where regions of “structured water” could as act as a 
platform initiating hydrolysis of the thioester bond in C3 to form C3(H2O), thus 
allowing for subsequent accommodation of factors B and D and assembly of fluid-
phase C3bBb convertases. Therefore, this study monitored PEG-mediated rises of the 
split-product Bb in serum, which is a specific marker of complement activation 
through the alternative pathway (Moghimi et al., 2004; Szebeni et al., 1998; Moghimi 
et al., 2006). In accordance with the above hypothesis, the results in Fig. 4.2a show 
that, on molar basis, the longer the PEG molecules the more effective they are in 
triggering alternative pathway activation. In the case of PEG1960, serum Bb levels 
were not elevated even at concentrations as high as 20 mM (40 mg/mL of serum), but 
the simultaneous increase in the serum levels of SC5b-9 and C3a-desArg (Fig. 4.1a, e) 
strongly indicate that PEG1960-mediated complement activation proceeds through 
other pathways (classical and/or lectin pathway).  
Activation of the alternative pathway by high Mw PEG species (Mw = 4240 gmol
-1
 or 
8350 gmol
-1
) may further represent amplification of C3 convertases initially triggered 
through C4-dependent pathway (Szebeni et al., 1994). In order to demonstrate that 
PEG molecules can directly trigger activation of the alternative pathway this study 
  
monitored Bb and SC5b-9 generation simultaneously in a C2-depleted human serum 
(Fig. 4.3a). With PEG8350 serum levels of both complement markers were 
significantly above background (Fig. 4.3a), thus showing the capability of these 
species to directly activate alternative pathway. On the contrary, PEG4240 only at 10 
mM concentration was able to trigger Bb generation in C2-depleted serum (Fig. 4.3a). 
Although, at lower PEG4240 concentrations (5 mM) neither serum Bb nor SC5b-9 
levels were elevated, significant rises in SC5b-9 levels above background in C2-
depleted serum was only demonstrable following restoration of C2 at physiological 
concentrations; this observation strongly suggest a role for the C4-dependent pathway 
and involvement of C4b2a convertases in subsequent assembly of the terminal 
complement complex.  
In a protein solution, PEGs, in a concentration-dependent manner, can favour the 
formation of protein crystals by decreasing the protein solubility through “depletion 
attraction”, but PEG can also induce other phase changes such as “liquid-liquid” 
phase separation, protein aggregation and the formation of gels (Asakura & Oosawa, 
1954; Tardieu et al., 2003). Results here therefore reasoned PEG-mediated triggering 
of the alternative pathway may in part arise from depletion of factor H, the major 
fluid-phase regulator of the alternative pathway (Pangburn et al., 1977). Factor H 
attenuates alternative pathway activation by inhibiting the binding of factor B to C3b, 
accelerating the decay of preformed C3Bb convertases and acting as a cofactor for the 
serine protease factor I to cleave C3b (Walport, 2001a,b). Western blot analysis of 
PEG4240- and PEG11600-induced protein aggregates in human serum has confirmed the 
presence of factor H (Fig. 4.3b). With PEG4240 treatment, factor H was only detectable 
when surfactant concentration was at 10 mM or above. These observations are in-line 
with PEG-mediated Bb generation in the C2-depleted serum (Fig. 4.3a). 
  
 
4.3.3 C4-Dependent complement activation 
C4d is a fluid phase degradation product of C4 cleavage, mediated by complement 
control protein C4bp and factor I, and an established marker of classical and lectin 
pathway activation (Moghimi et al., 2006; Scharfstein et al., 1978; Fujita et al, 1998). 
Accordingly, further indication for the involvement of C4-dependent pathway was 
obtained by showing PEG-mediated rises of C4d in both normal and C2-depleted 
human serum (Fig. 4.2b & 4.3a). Low Mw PEG molecules (eg, PEG1960) and PEG4240 
(at concentrations below 10 mM), therefore, seem to activate complement exclusively 
via C4-dependent pathway, whereas PEG4240 (at 10 mM) and higher Mw PEG species 
trigger complement through both C4-dependent and alternative pathways. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 4.2a. Elevation of complement split-product Bb as a function of PEG molar 
concentration and molecular mass. Serum source was the same as in Fig. 4.1. 
Serum Bb background level was 0.42 ± 0.06 µg/mL. Similar patterns were further 
obtained with 4 other tested sera from separate individuals. Significant difference with 
respect to background (saline-treated serum): *p<0.05, **p<0.01.  
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 4.2b. Elevation of complement split-product C4d as a function of PEG molar 
concentration and molecular mass. Serum source was the same as in Figure 4.1. 
Serum C4d background level was 2.24 ± 0.16 µg/mL. Similar patterns were further 
obtained with 4 other tested sera from separate individuals. Significant difference with 
respect to background (saline-treated serum): all treatments elevated serum C4d levels 
significantly (p<0.05 in all cases). 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 4.3a. PEG-mediated elevation of complement activation products SC5b-9, 
Bb and C4d in C2-depleted human serum. SC5b-9, Bb and C4d background levels 
(saline-treated serum) were 1.83 ± 0.15 µg/mL, 0.79 ± 0.07 µg/mL and 3.88 ± 0.17 
µg/mL, respectively. Significant difference with respect to background (saline-treated 
serum): *p<0.05. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 4.3b. Western blot analysis of PEG-induced protein aggregates for factor H 
in normal serum. A commercially purified factor H was included as a positive 
control with immunoblots.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Next, this experiment examined through which pathway(s) PEGs could initiate C4 
cleavage. Complement activation through the classical pathway may be initiated by 
binding of naturally occurring antibodies against PEGs. Since Ca
2+
 is essential for the 
operation of the classical pathway (Moghimi et al., 2004 and 2006; Szebeni et al., 
1994 and 1998) first this experiment measured PEG1960-mediated rises of both C4d 
and SC5b-9 in sera of 5 healthy individuals by excluding Ca
2+
 from the assay 
(PEG1960 was used since it activated complement only through C4-dependent 
pathway). Remarkably, in all EGTA/Mg
2+
 supplemented sera, PEG1960 treatment 
significantly elevated both C4d and SC5b-9 levels above background (Fig. 4.4a), thus 
eliminating the role of classical pathway. With longer PEG chains, C4d levels in 
EGTA-chelated sera were also elevated (not shown). As a control, Ca
2+
 chelation in 
serum halted cholesterol-rich liposome-mediated rises of C4d but not SC5b-9 level 
(Fig. 4.4b), as these vesicles activate complement through both antibody-mediated 
classical pathway as well as alternative pathway (Szebeni et al., 1994 and 1998). 
However, PEG-mediated complement activation through the classical pathway in a 
serum with high titer of anti-PEG antibodies, notably of IgM class still cannot be 
disregarded. To further eliminate the role of classical pathway, this study examined 
PEG-mediated C4d rises in a C1q-depleted serum and the results in Fig. 4.5a 
corroborate these findings with EGTA-chelated sera. In addition, these results further 
exclude a direct role for C1q in PEG-mediated complement activation.  
Exclusion of the C1q-dependent pathway in PEG-mediated complement activation 
raises the question as to whether PEGs are capable of triggering complement via the 
lectin pathway. The lectin pathway initiator complex consists of either mannan-
binding lectin (MBL) or ficolin and three MBL-associated serine proteases 1–3 
(MASP-1, -2, -3) and the smaller non-enzymatic component sMAP (Fujita, 2002; 
  
Wallis, 2002). MBL bind to monosaccharides such as mannose, fucose and N-
acetylglucosamine with affinities typically in mM range, where the sugar binding site 
is localized around one of two Ca
2+
 sites of the carbohydrate-recognition domain 
(CRD) (Wallis, 2002; Lee et al., 1991; Jack et al., 2001; Weis et al., 1992). Equitorial 
hydroxyl groups at the 3- and 4-OH positions of the sugar residue serve as 
coordination ligands for the Ca
2+ 
(Weis et al., 1992). Additional coordination ligands 
are further provided by asparagine and glutamic acid residues in the CRD that form 
hydrogen bonds with the equatorial 3-OH and the 4-OH groups. Ficolins, on the other 
hand, express specificity only for sugars with N-acetylated groups (Fujita, 2002) as 
well as acetylated compounds, relatively independent of the structure of the acetylated 
molecule (Krarup et al., 2004).  
Next this experiment eliminated the possible involvement of MBL in PEG-mediated 
complement activation, since PEG treatment of C1q-depleted serum in the presence of 
25 mM D-mannose also elevated C4d levels but not when mannose was replaced with 
N-acetylglucosamine (Fig. 4.5a). D-galactose was used as a nonantagonist (negative 
control). In addition, the OH groups at PEG termini seem to play a minor role in 
complement activation since acetylated PEGs also raised C4d levels equally in C1q-
depleted serum (Fig. 4.5a). These observations therefore suggest a likely role for 
ficolins in PEG-mediated complement activation. PEG-mediated C4d elevation in 
C1q-depleted serum was further inhibited by Futhan (a broad-spectrum serine 
protease inhibitor) (Pfeifer et al., 1999), thus indicating a role for activation of a 
serine protease (presumably MASP-2) for subsequent C4 cleavage.  
 
 
  
 
 
 
Fig. 4.4a. Comparison of PEG- and cholesterol-rich liposome-mediated 
complement activation in EGTA/Mg
2+
-treated sera. Sera from 5 healthy male 
subjects were used (designated as S1–S5): PEG-mediated elevation of complement 
activation products. In all cases p<0.05.  
 
 
 
 
 
 
 
  
 
 
Fig. 4.4b. Comparison of PEG- and cholesterol-rich liposome-mediated 
complement activation in EGTA/Mg
2+
-treated sera: The effect of liposomes (3 mg 
lipid/mL) on serum SC5b-9 and C4d levels of subject 3 (S3) in the absence and 
presence of EGTA/Mg
2+
. In all cases p<0.05 with the exception of liposome-mediated 
C4d level in S3 + EGTA/Mg
2+
 (not significant) when compared with corresponding 
background levels of complement activation products. 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 4.5a. The effect of native and acetylated PEG4240 on C4d generation in C1q-
depleted human serum. The C4d background level was 3.64 ± 0.37 µg/mL. PEG-
mediated C4d levels were also measured by prior treatment of serum with sugars (25 
mM final concentration) or Futhan (150 µg/mL final concentration). Sugar or Futhan 
addition had no significant effect on C4d background levels.  Significant difference to 
the respective background: *p<0.05.  
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig. 4.5b.  The chemical structure of acetylated PEG. For reaction chemistry see 
Materials and Methods. 
 
 
 
 
 
 
 
 
 
 
 
 
  
A recent study has shown that after precipitation of serum proteins with 4% w/v 
PEG6000, approximately 80% of both L- and H-ficolins remained in the supernatant 
while the amounts of MBL and C1q were reduced dramatically (Krarup et al., 2004). 
With lower PEG concentrations (2% w/v) virtually all ficolins were recoverable in the 
supernatant (Krarup et al., 2004). Since we have observed C4d elevations in serum 
with both PEG4240 and PEG8350 at concentrations even below 2%, then it is rather 
unlikely that the apparent PEG-mediated lectin pathway activation may 
predominantly arise from binding of ficolin-MASPs to exposed substrates from 
aggregated proteins. Thus, these observations raise an intriguing question as to 
whether PEGs can directly interact with ficolins and activate MASP-2. Detailed 
investigations are currently in progress to address this issue. 
 
4.3.4 Kinetics of PEG-mediated complement activation 
The results in Fig. 4.6 show the kinetics of PEG-mediated complement activation. 
PEG11600-mediated elevation of serum SC5b-9 and Bb levels proceeded on a time 
scale of minutes and reached plateau at about 5 min (Fig. 4.6). Similar profiles were 
also observed with PEG4240 (10 mM) and PEG8350 (not shown). Remarkably, such 
complement activation time scales are in line with the rapidity of the observed acute 
adverse reactions or cardiovascular collapse in animals receiving intravenous 
injections of PEG-containing medicines.  
 
 
 
 
 
  
 
 
 
Fig. 4.6a. PEG11600-mediated SC5b-9 generation in a normal serum over time. PEG 
concentration was 1.5 mM.  
 
 
 
 
 
 
 
 
 
 
  
 
Fig. 4.6b. PEG11600-mediated Bb generation in a normal serum over time. PEG 
concentration was 1.5 mM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4.4 Conclusion 
Adverse non-IgE-mediated hypersensitivity reactions, which are associated with 
cardiac anaphylaxis and rapid haemodynamic collapse, are known to occur in some 
humans and animals who have received intravenous formulations of radiocontrast 
media, nonionic drug solubilizers (eg, cremophor EL, poloxamers) and particulate 
nanomedicines. These reactions arise at first treatment without prior sensitization (and 
may lessen or disappear on later treatments) and are strongly believed to be secondary 
to complement activation through the generation of anaphylatoxins C3a and C5a. 
These reactions have been reported to occur in some patients within 5-10 minutes of 
infusion in up to 45% of the individuals receiving nanomedicines (Szebeni, 2005). 
Unexplained, but similar acute adverse reactions also occur to intravenous medicines 
with high contents of poly(ethylene glycol) (PEG) as solubilizer. Although PEG is 
often perceived to be immunologically inert and safe, here this study demonstrates 
that near-monodisperse endotoxin-free PEGs, at clinically relevant concentrations, 
can trigger complement activation in human sera on a time scale of minutes (reflected 
in significant rises in SC5b-9, C4d, Bb and C3a-desArg levels). With the aid of sera 
deficient in either C2 or C1q, results further demonstrate that, depending on PEG 
concentration and Mw, complement activation proceeds either exclusively through 
lectin pathway or through both lectin and alternative pathways. Although the highly 
hydrated PEG backbone could as act as a platform initiating hydrolysis of the 
thioester bond in C3 to form C3(H2O), activation of the alternative pathway was also 
linked to PEG-mediated partial depletion of the fluid-phase regulator factor H. 
Competitive studies in C1q-depleted serum with D-mannose and N-
acetylglucosamine further suggested a likely role for ficolins in 
PEG/diacetylatedPEG-mediated C4d elevation. Complement activation may therefore 
  
provide a plausible explanation to the previously reported unexplained anaphylaxis or 
the referred cardiovascular collapse in species that have received medicines 
containing high levels of PEG as solubilizer/carrier. Results in this study are also 
relevant to potential therapeutic applications of PEGs (as in spinal cord injury and 
traumatic axonal brain injury) and warn about possible acute PEG infusion-related 
reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter five 
 
Activation of the Human Complement System by 
Cholesterol-Rich and PEGylated Liposomes—Modulation of 
Cholesterol-Rich Liposome-Mediated Complement 
Activation by Elevated Serum LDL and HDL Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5.1 Introduction 
A number of studies have revealed that immediately after infusion of liposomes non-
IgE-mediated hypersensitivity reactions occur in some individuals (Levine et al., 
1991; Ringdén et al., 1994). The symptoms include cardiopulmonary distress such as 
dyspnea, tachypnea, hypertension/hypotension, chest pain, and back pain. Unlike 
Type I allergy, the response to liposomes arises at the first exposure without prior 
sensitization, and the symptoms may lessen or disappear on later treatment. Such 
pseudoallergic reactions are also common following infusion of stealth PEGylated 
liposomes (Alberts et al., 1997), for instance the frequency of pseudoallergic 
responses among 705 patients treated with Doxil
®
 (PEGylated liposomes with 
entrapped doxorubicin) was 6.8% (Dezube, 1996). Recent in vitro and in vivo studies 
have indicated that these reactions could arise through rapid production of 
anaphylatoxins (C3a, C5a) via complement activation, and the individual sensitivity 
to anaphylatoxin-derived mediators (Szebeni et al., 2000; Chanan-Khan et al., 2003). 
Liposome-encapsulated haemoglobin has potential application as a red cell substitute 
in transfusion medicine. Because of complement activation, the potential use of 
liposomes (with encapsulated haemoglobin) as a substitute for shed blood in trauma 
patients, who are prone to develop adult respiratory distress syndrome partly as a 
consequence of injury-related complement activation, could be problematic (Moore, 
1994). Thus, further complement activation might aggravate the clinical state of 
trauma patients.  
Adverse non-IgE-mediated hypersensitivity reactions also occur following infusion 
of Fluosol-DA (perfluorochemicals emulsified with the nonionic 
polyoxyethylene/polyoxypropylene block copolymer poloxamer 188), which are 
secondary to complement activation by poloxamer 188 (Temper et al., 1984; 
  
Police et al., 1985; Lustig et al., 1989). Interestingly, a low incidence of 
complement activation and complement-mediated adverse events has been 
observed following intravenous infusion of Fluosol-DA in subjects with abnormal 
or elevated LDL and HDL profiles (Vercellotti et al., 1982; Kent et al., 1990). On 
the basis of these reports, it has recently been demonstrated that the elevation of 
serum concentrations of LDL and HDL cholesterol relevant to two clinical 
situations exerted a protective role against poloxamer-mediated complement 
activation (Moghimi et al., 2004).  
Therefore, this study examined whether the elevation of human serum LDL and HDL 
cholesterol levels can exert a protective role against cholesterol-rich (45 mol% 
cholesterol) liposome-mediated complement activation in vitro, since cholesterol-rich 
liposomes can interact with lipoproteins. The effect of lipoproteins was also studied 
on liposome-induced (and complement-mediated) cardiovascular distress in the 
established porcine model.   
 
5.2 Materials and Methods 
5.2.1 Materials 
Dimyristoylphosphatidylcholine, Dimyristoylphosphatidylglycerol, Cholesterol and 
Zymosan were all purchased from Sigma, UK. 
Complement enzyme-linked immunosorbent assay kit was purchased from Quidel 
Co., San Diego, CA, USA.  
HDL and LDL were purchased from Calbiochem, Germany.  
Chloroform was purchased from Sigma-Aldrich-UK.  
 
 
  
5.2.2 Methods 
5.2.2.1 Preparation of liposomes 
In accordance with earlier observations, large multilamellar liposomes consisting 
of dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol, and 
cholesterol (50:5:45 mole ratios) were used, which are very potent at inducing 
pulmonary hypertension in pigs, resulting in circulatory collapse and even death 
(Szebeni et al., 2000). Liposomes were prepared by hydrating the dried lipid film 
with chloroform, and then the organic solvent was removed using a rotary 
evaporator. The LML liposomes were then suspended in 10 mM PBS. 
 
5.2.2.2 Subject and collection of serum specimen 
Blood was drawn from healthy volunteers according to protocols approved by the 
school of pharmacy and the clinical centre at University of Brighton. Blood was 
allowed to clot at room temperature and serum was prepared, and then stored at -80 
°C. Serum samples were thawed and kept at 4 °C before incubation with test agents. 
 
5.2.2.3 Assay of in vitro complement activation 
Liposome-mediated complement activation through the classical and alternative 
pathways in undiluted healthy human serum was monitored by measuring the 
production of the S-protein-bound form of the terminal complex, SC5b-9 using an 
enzyme-linked immunosorbent assay kit according to the manufacturer’s protocol 
(Moghimi et al., 2004). 
 
 SC5b-9 is the soluble, S-protein-bound form of the terminal complex, a sensitive 
measure of C5a formation through both the classical and the alternative pathways, 
  
while Bb is the proteolytically active fragment of factor B, a specific marker of 
complement activation through the alternative pathway. The test agents were 
incubated with serum in a shaking water bath (80 rpm cycle) for 30-60 minutes at 37 
°C at an activator to serum ratio of 1:5. Typically, 5-10 µL of the testing agent stock 
solution was added to 40 µL of serum placed in Eppendorf tubes. The reaction was 
stopped by adding 20 volumes of PBS that contained 2 mM EDTA, 25 mg/mL bovine 
serum albumin, 0.05% Tween 20 and 0.01% thiomerosal (pH 7.4). The final 
concentration of liposomes in serum was 5 mg/mL. Zymosan (5 mg/mL) was used as 
a positive control to confirm the presence of a functional complement system in 
human serum (Szebeni et al., 1998). Levels of produced SC5b-9, Bb, C4d and C3a-
desarg were measured with the respective ELISA kits. 
 
5.2.2.4 In vivo Closed-Chest Instrumented Pig 
For in vivo experiments female Yorkshire swine (25–40 kg) were sedated with i.m. 
ketamine (500 mg), anesthesized with 1% halotane, and instrumented as described in 
detail by (McLoughlin, et al., 1996; Szebeni et al., 1999). In brief, a catheter was 
advanced via the right internal jugular vein into the pulmonary artery to measure 
pulmonary artery pressure (PAP), central venous pressure (CVP), and cardiac output 
(CO); another was advanced through the right femoral artery into the proximal aorta 
to measure systemic arterial pressure (SAP) and for blood sampling; and a third 
catheter was placed into the left ventricle through the left femoral artery to monitor 
left ventricular end-diastolic pressure (LVEDP). Systemic vascular resistance (SVR) 
and pulmonary vascular resistance (PVR) were calculated from SAP, PAP, CO, CVP, 
and LVEDP by standard formulas (McLoughlin et al., 1996). All procedures on pigs 
were performed in accordance with the guidelines of the Committee on Animal Care 
  
of the Uniformed Services University of the Health Sciences. Indeed, the porcine 
model is well established and provides highly sensitive detection of cardiopulmonary 
side effects of liposomes resulting from complement activation (Szebeni et al., 1999). 
Blood pressure and leads II and V5 of the ECG were recorded continually.  
 
5.3 Results and Discussion 
The results in Fig. 5.1 show a dramatic rise in serum SC5b-9 level after 30 min 
incubation with liposomes, compared to the control incubation (serum supplemented 
with phosphate buffered saline, pH 7.2, in place of liposomes), thus confirming the 
complement activating nature of these vesicles. The cholesterol and triglyceride levels 
of the serum were normal, and approximately 180 mg/dL and 200 mg/dL, 
respectively. The additive effect of purified serum HDL and LDL on liposome-
mediated complement activation was monitored next. The addition of purified HDL to 
serum increased cholesterol levels by 25–30%, which is considered beneficial by the 
National Cholesterol Education Program Expert Panel (NIH, USA), and represents a 
target for many therapies. The addition of purified LDL doubled serum cholesterol 
levels; a situation similar to that encountered in heterozygous familial 
hypercholesterolemia (Moghimi et al., 2004). Elevation of both serum HDL and LDL 
levels had no effect on SC5b-9 production and the results were comparable to that of 
the control incubation. Remarkably, elevated serum HDL and LDL levels suppressed 
liposome-mediated SC5b-9 production significantly (p<0.01). This suppression was 
more effective with LDL than HDL, which may be due to preferred fusion of 
cholesterol-rich liposomes with LDL particles (Zakharovats et al., 1994). 
Manipulation of serum lipoprotein levels had no effect on zymosan-mediated 
complement activation.  
  
When injected intravenously as a bolus in pigs via the jugular vein, liposomes (5 
mg/mL) induced an immediate circulatory collapse (Fig. 5.2), which was 
intervened with epinephrine administration (0.5 mg/kg) and resuscitation. These 
observations were in accord with previous studies (Szebeni et al., 1999 and 2000). 
After normalization of all haemodynamic parameters, animals received an 
injection of liposomes preincubated with human lipoproteins for 10 min at room 
temperature. For example, following treatment with HDL (1.4 mg/mL total 
protein, 0.37 mg/mL cholesterol, 0.12 mg/mL triglyceride), liposome-induced drop 
of systemic arterial pressure was slow and extended (Fig. 5.2), suggesting that 
surface-associated lipoprotein particles (or apolipoproteins) lessened the adverse 
haemodynamic changes, possibly as a consequence of suppressed complement 
activation in vivo (although other important physiological changes on the system 
might play a role, e.g., the renin angiotensin system and corticosteroid release). 
Since liposome-mediated haemodynamic changes are not tachyphylactic (Szebeni 
et al., 1999), without lipoprotein pre-treatment, the second injection would have 
caused very similar anaphylactic shock as observed after the first liposomal 
injection. In contrast to liposomes and liposome-lipoprotein preparations, injection 
of HDL and LDL particles alone was harmless and no haemodynamic changes 
were observed. Based on earlier studies using fluorescence-activated cell sorting 
analysis, this study suggested that the binding of naturally occurring IgG and IgM 
antibodies to liposomes could be the rate-limiting factor to both complement 
activation (predominantly via the classical pathway) and subsequent 
haemodynamic changes in the porcine model (Szebeni et al., 2000). Therefore, 
adherence and/or fusion of HDL and LDL particles, or a mixture of 
apolipoproteins such as apoB-100, apoA-I, apoA-II, and apoA-IV to liposomes 
  
may offer some protection against antibody and complement protein binding, and 
hence suppressing complement activation. As mentioned earlier, other chapters 
have investigated the effect of liposomal lipid composition, cholesterol content, 
and size on complement activation. Nevertheless, considering the abundance of 
lipoproteins in the blood, these observations predict a yet unrecognized and 
presumably universal modulatory function of lipoproteins/apolipoproteins on 
complement activation. 
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Fig. 5.1. The effect of human lipoproteins on liposome-mediated complement activation
human serum (liposomes mean size was 450± 80 nm).
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Fig. 5. 2. The effect of human lipoprotein on liposome-mediated complement activation: Mean systemic arterial 
blood pressure in a typical pig (out of 3) following injection of liposomes. Liposomes and liposome/HDL (5 mg 
liposomal lipid with a mean size of 450± 80 nm) were injected in a total volume of 1.0 ml. MLV liposomes were 
injected first (the arrow indicates the point of injection), the pigs circulatory collapse was intervened with epinephrine 
(0.5 mg/kg) and normalization of all haemodynamic parameters was achieved.  
 
 
 
 
 
 
 
 
 
 
  
5.4 Conclusion 
Intravenously infused liposomes may induce cardiopulmonary distress in some human 
subjects, which is a manifestation of “complement activation-related pseudoallergy”. 
This study has now examined liposome-mediated complement activation in human 
sera with elevated lipoprotein (LDL and HDL) levels, since abnormal or racial 
differences in serum lipid profiles seem to modulate the extent of complement 
activation and associated adverse responses. In accordance with other earlier 
observations, cholesterol-rich (45 mol% cholesterol) liposomes activated human 
complement, as reflected by a significant rise in serum level of S-protein-bound form 
of the terminal complex (SC5b-9). However, liposome-induced rise of SC5b-9 was 
significantly suppressed when serum HDL cholesterol levels increased by 30%. 
Increase of serum LDL to levels similar to that observed in heterozygous familial 
hypercholesterolemia also suppressed liposome-mediated SC5b-9 generation 
considerably. While intravenous injection of cholesterol-rich liposomes in to pigs was 
associated with an immediate circulatory collapse, the drop in systemic arterial 
pressure following injection of liposomes preincubated with human lipoproteins was 
slow and extended. Therefore, surface-associated lipoprotein particles (or 
apolipoproteins) seem to lessen liposome-induced adverse haemodynamic changes, 
possibly as a consequence of suppressed complement activation in vivo.  
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Chapter six: 
 
General conclusions and suggestions for future work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
This study has elaborated on understanding of the molecular basis of complement 
activation by PEGylated nanoparticulate agents as well as by PEG in solution. 
Initially, the involvement of the anionic charge localized on the phosphate oxygen 
moiety of phospholipid-mPEG conjugates in PEGylated liposome-mediated 
complement activation and anaphylatoxin production was demonstrtaed. 
Subsequently, liposomes bearing a nonionic 1-O-phospholipid-mPEG conjugate that 
do not activate complement in human and rat sera were designed successfully. This is 
a critical step towards development of safer zwitterionic vesicles, which are 
temperature sensitive as well as susceptible to degradation by sPLA2. These 
observations and strategies not only provide a rational conceptual basis for design of 
safer PEGylated liposomes for site-specific drug delivery and targeting, but also 
highlight the importance of linkage chemistry in complement activation. The latter is 
of importance for surface engineering of implants and nanodevices with mPEG 
conjugates and related polymers for in vivo applications. It is still needed to fully 
understand how methylation of the phosphate oxygen can affect antibody and C1q 
accommodation on the liposome surface. Understanding of these events may 
eventually lead to prediction and elimination of subjects at risk, and even enhance the 
utility of PEGylated liposomes bearing anionic phospholipid-mPEG conjugates 
among low risk individuals.  
Others have recently synthesized a range of neutral lipopolymers, such as distearoyl 
glycerol (carbamate-linked)mPEG and variations thereof for liposome engineering 
(Garbuzenko et al., 2005). Remarkably, preliminary investigations have also 
demonstrated that such lipopolymer-incorporated liposomes are, indeed, poor 
activators of the human and porcine complement system when compared to vesicles 
bearing anionic phospholipid-mPEG conjugates ( Zalipsky & Barenholz, 2004), thus 
  
supporting the stated hypothesis. Other related uncharged lipid conjugates for 
construction of stealth liposomes includes mPEG-substituted synthetic ceramides 
(Webb et al., 1998), but such conjugates generally exhibit poor packing into the 
phospholipid bilayer. 
The work described in this thesis also is the first demonstration of PEGylated SWNT-
mediated complement activation at both in vitro and in vivo levels. As to the 
molecular basis of PEGylated SWNT-mediated complement activation via the lectin 
pathway, at present I have only speculated a possible role for MBL and/or ficolin 
binding to some structural determinants of SWNTs, leading to subsequent MASP-2 
activation, C4 cleavage and formation of C42a convertases. The structural features 
required for MBL and/or ficolin binding are presumably expressed in a simultaneous 
manner by both PEG chains and the nanotube surface, and therefore complement 
activation may have been triggered from inadequate surface protection of a certain 
population of SWNTs by PEG5000-PL conjugates. Surface heterogeneity (with some 
populations poorly protected by PEG chains) may also explain the observed rapid 
deposition of a significant fraction of intravenously injected PEGylated SWNT in 
liver and spleen macrophages through blood opsonization events, such as complement 
fixation (Liu et al., 2007). Therefore, for better protection against complement 
activation, PEG-PL conjugates of longer PEG chains or those displaying branched 
PEG chains may be used. Indeed, such surface engineered SWNTs have recently 
provided improved blood pharmacokinetics (Liu et al., 2008). Also, earlier work with 
PEGylated liposomes has identified a role for the net anionic charge on the phosphate 
moiety of the PEG-PL conjugate, which in concert with specific structural moiety of 
the lipid bilayer orchestrate vesicular-mediated complement activation through 
antibody binding (Szebeni, 2005). A similar mode of action could also operate with 
  
PEGylated SWNTs, where the surface may activate MASP-2 directly or partly 
through electrostatic interaction with MBP and/or ficolins. Non-ionic PEG-lipid 
conjugates may be used for SWNT stabilization to establish whether the anionic 
phosphate-oxygen is of central importance in complement activation. Finally, 
experiments in pigs and dogs would be prudent to establish whether PEGylated 
SWNT can induce complement activation-related pseudoallergy. The pig and dog are 
established models for assessing such acute reactions to nanomedicines, although the 
nature of responses is different (Andersson et al., 2002; Moghimi & Szebeni, 2003). 
For example, minute amounts of liposome administration into pigs induces rapid 
haemodynamic changes such as a massive rise in pulmonary arterial pressure, and a 
decline in systemic arterial pressure, cardiac output and left ventricular end-diastolic 
pressure. In dogs, haemodynamic responses are less dramatic, but remarkably dogs 
display considerable vegetative neural dysfunction, presumably indicating a set of 
unique interactions between the immune and the neural systems in this species 
(Moghimi & Szebeni, 2003). 
Perhaps the most intriguing observation reported in this thesis was the ability of 
PEGs, in soluble form but at clinically relevant concentration, to trigger complement 
activation through both alternative and lectin pathways. These results are relevant to 
potential therapeutic applications of PEGs, as in spinal cord injury and traumatic 
axonal brain injury, and warn about possible acute PEG infusion-related reactions. 
Similar to binding of allergens to IgE on the surface of mast cells and basophils, 
complement anaphylatoxins can trigger immediate release of various proinflammatory 
mediators (prostaglandins, leukotrienes, etc.) from these cells as well as macrophages 
in contact with the blood. This cascade of secondary mediators substantially amplifies 
effector immune responses and may induce anaphylaxis in sensitive individuals. 
  
Indeed, recent studies in pigs have demonstrated that systemic complement activation 
(eg, induced following intravenous injection of PEGylated liposomes) can underlie 
cardiac anaphylaxis where C5a played a causal role. Cardiac mast cells express high-
affinity receptors for complement anaphylatoxins and their triggering induces the 
release of a variety of inflammatory mediators and vasoactive molecules. C5a was 
also shown to intensify the allergen-induced anaphylactic crises in isolated, perfused 
guinea pig hearts. Additionally, complement activation may therefore provide a 
plausible explanation to the previously reported unexplained anaphylaxis or the 
referred cardiovascular collapse in species that have received medicines containing 
high levels of PEG as solubilizer/carrier.  In light of these observations, future 
experiments in relevant animal models and with anti-C5a antibodies are necessary to 
establish whether PEG-mediated peripheral complement activation can explain 
cardiac anaphylaxis. Finally, as a spin-off, PEGs may provide an additional platform 
for elucidation of ligand topology/structure for the pattern recognition molecules L- 
and H-ficolins, and subsequently illuminate the role of ficolins in defense as well as in 
endogenous homeostatic mechanisms. 
In summary, hypersensitivity reactions caused by nanomedicines and their polymeric 
consitutes may be strongly linked to complement activation and generation of 
anaphylatoxins. Hypersensitivity reactions arising as a consequence of complement 
activation could be life-threatening. Therefore, monitoring the formation of SC5b-9 in 
patients prior to nanomedicine infusion could be a significant factor, but since SC5b-9 
depends completely on C9 polymerization, and hence this might be influenced during 
the assay by a number of biological parameters, this might not give the best indication 
for patient preselection. However, simultaneous monitoring of both SC5b-9 and 
anaphlatoxins (C3a and C5a) generation could provide a better rational. General 
  
precautions may also be followed to tackle nanomedicine-related complement 
hypersensitivity reactions. Some can be non specific (slow infusion of nanomidicines 
and pre-medication with steroids as anti histamines) or specific (Cox inhibitors as 
indomethacin, or complement inhibitors). 
Finally, this study has examined the effect of elevated lipoprotein (LDL and HDL) 
levels on liposome-mediated complement activation in human serum.  Cholesterol 
rich liposomes activated human complement. However, liposome-induced 
complement activation was significantly suppressed when serum HDL or LDL levels 
increased. Remarkably, in-vivo studies showed that surface-associated lipoprotein 
particles (or apolipoproteins) seem to lessen liposome-induced adverse 
haemodynamic changes, possibly as a consequence of suppressed complement 
activation in vivo.  
It would be worthwhile to extend the complement activation studies to other nano 
particles or non-ionic surfactants. For instance, Cremophor EL has shown 
hypersensitivity reactions which were related strongly to complement activation. 
Detailed study might be useful in revealing the exact mechanism in which Cremophor 
EL-induced complement activation operates, consequently, this will help in 
developing new attempts towards controlling this side effect.  
As noticed in PEG-induced complement activation, strong evidence suggested the 
involvement of the lectin pathway. Further studies needed to explore the possibility of 
PEG-ficolin interaction as a causative factor of lectin pathway activation. The results 
obtained from in vitro biological performance (complement activation) were found to 
correlate closely with in vivo studies in rats. It would be beneficial if more in vivo 
studies are carried out using bigger animals (dogs and pigs) as different reactions are 
expected with bigger animals. This would give a better idea about the adverse 
  
haemodynamic changes in vivo and a good chance towards development of relatively 
safer drug-carriers.  
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